81437 Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma,malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must includesequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL

81438 Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma,malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analysesfor SDHB, SDHC, SDHD, and VHL

81442 Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome,LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencingof at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1,SHOC2, and SOS1

81490 Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum,prognostic algorithm reported as a disease activity score

81493 Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing wholeperipheral blood, algorithm reported as a risk score

81525 Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score

81528 Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers(KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool,algorithm reported as a positive or negative result

81535 Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain andmorphology, predictive algorithm reported as a drug response score; first single drug or drug combination

81536 Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain andmorphology, predictive algorithm reported as a drug response score; each additional single drug or drugcombination (List separately in addition to code for primary procedure)

81538 Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic andpredictive algorithm reported as good versus poor overall survival

81540 Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixedparaffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype

81545 Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reportedas a categorical result (eg, benign or suspicious)

81595 Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection riskscore

88350 Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately inaddition to code for primary procedure)

2015 2016

Code Descriptor Change CrosswalkCode

Descriptor Advice

81210 BRAF (v-raf murine sarcomaviral oncogene homolog B1)(eg, colon cancer), geneanalysis, V600E variant

Revised -- BRAF (vB-raf murinesarcoma viral Rafproto-oncogene homologB1, serine/threoninekinase) (eg, colon cancer,melanoma), gene analysis,V600E variant(s)

CPT® 2016 revises 81210to use the official name forthe BRAF gene, “B-Rafproto-oncogene,serine/threonine kinase,”and to add melanoma asan example of conditionsthat a BRAF genemutation might affect. Theupdated code alsobroadens the definition tospecify any V600 variants,not just V600E.

81275 KRAS (v-Ki-ras2 Kirsten ratsarcoma viral oncogene) (eg,carcinoma) gene analysis,variants in codons 12 and 13

Revised -- KRAS (v-Ki-ras2 Kirstenrat sarcoma viraloncogene homolog) (eg,carcinoma) gene analysis,variants in codons 12 and13; variants in exon 2 (eg,codons 12 and 13)

CPT® 2016 revises 81275to use the official name forthe KRAS gene, “Kirstenrat sarcoma viraloncogene homolog.” Theupdated code alsobroadens the definition tospecify any mutation onexon 2, with examples ofcodons 12 and 13. Therevisions should notchange how you use thecode.

81355 VKORC1 (vitamin K epoxidereductase complex, subunit 1)(eg, warfarin metabolism),gene analysis, commonvariants (eg, -1639/3673)

Revised -- VKORC1 (vitamin Kepoxide reductasecomplex, subunit 1) (eg,warfarin metabolism),gene analysis, commonvariants(s) (eg,-1639/36731639G>A,c.173+1000C>T)

CPT® 2016 revises 81355to update the example ofcommon variants listed inthe code, from -1639/3673to -1639G>A,c.173+1000C>T. Therevisions should notchange how you use thecode.

81401 Molecular pathologyprocedure, Level 2 (eg, 2-10SNPs, 1 methylated variant, or1 somatic variant [typicallyusing nonsequencing targetvariant analysis], or detectionof a dynamic mutationdisorder/triplet repeat)

ABCC8 (ATP-binding cassette,sub-family C [CFTR/MRP],member 8) (eg, familialhyperinsulinism), commonvariants (eg, c.3898-9G>A[c.3992-9G>A], F1388del)

ABL (c-abl oncogene 1,receptor tyrosine kinase) (eg,acquired imatinib resistance),T315I variant

ACADM (acyl-CoAdehydrogenase, C-4 to C-12straight chain, MCAD) (eg,medium chain acyldehydrogenase deficiency),commons variants (eg, K304E,Y42H)

Revised -- Molecular pathologyprocedure, Level 2 (eg, 2-10 SNPs, 1 methylatedvariant, or 1 somaticvariant [typically usingnonsequencing targetvariant analysis], ordetection of a dynamicmutation disorder/tripletrepeat)

ABL1 (ABL (cproto-abloncogene 1, non-receptortyrosine kinase) (eg,acquired imatinibresistance), T315I variant

DEK/NUP214 (t(6;9))

(eg, acute myeloidleukemia), translocationanalysis, qualitative, andquantitative, if performed

IGH@/BCL2 (t(14;18))

(eg, follicular lymphoma),translocation analysis;

CPT® 2016 revises81401, which representsall the technical work tocomplete just one specificmolecular test listed underthe code. The revisioninvolves adding somelisted tests, such asDEK/NUP214 (t(6;9))(e.g., acute myeloidleukemia), translocationanalysis, qualitative, andquantitative, if performedand IGH@/BCL2 (t(14;18))(e.g., follicular lymphoma),translocation analysis;single breakpoint (e.g.,major breakpoint region[MBR] or minor clusterregion [mcr]), qualitative orquantitative (When bothMBR and mcr breakpointsare performed, use81402). Each year, CPT®may add, delete, or revisesome tests listed undereach Tier 2 test level.

ADRB2 (adrenergic beta-2receptor surface) (eg, drugmetabolism), common variants(eg, G16R, Q27E)

AFF2 (AF4/FMR2 family,member 2 [FMR2]) (eg, fragileX mental retardation 2[FRAXE]), evaluation to detectabnormal (eg, expanded)alleles

APOB (apolipoprotein B) (eg,familial hypercholesterolemiatype B), common variants (eg,R3500Q, R3500W)

APOE (apolipoprotein E) (eg,hyperlipoproteinemia type III,cardiovascular disease,Alzheimer disease), commonvariants (eg, *2, *3, *4)

AR (androgen receptor) (eg,spinal and bulbar muscularatrophy, Kennedy disease, Xchromosome inactivation),characterization of alleles (eg,expanded size or methylationstatus)

ATN1 (atrophin 1) (eg,dentatorubral-pallidoluysianatrophy), evaluation to detectabnormal (eg, expanded)alleles

ATXN1 (ataxin 1) (eg,spinocerebellar ataxia),evaluation to detect abnormal(eg, expanded) alleles

ATXN2 (ataxin 2) (eg,spinocerebellar ataxia),evaluation to detect abnormal(eg, expanded) alleles

ATXN3 (ataxin 3) (eg,spinocerebellar ataxia,Machado-Joseph disease),evaluation to detect abnormal(eg, expanded) alleles

ATXN7 (ataxin 7) (eg,spinocerebellar ataxia),evaluation to detect abnormal(eg, expanded) alleles

ATXN8OS (ATXN8 oppositestrand [non-protein coding])(eg, spinocerebellar ataxia),evaluation to detect abnormal(eg, expanded) alleles

ATXN10 (ataxin 10) (eg,spinocerebellar ataxia),evaluation to detect abnormal

single breakpoint (eg,major breakpoint region[MBR] or minor clusterregion [mcr]), qualitative orquantitative (When bothMBR and mcr breakpointsare performed, use 81402)

(eg, expanded) alleles

CACNA1A (calcium channel,voltage-dependent, P/Q type,alpha 1A subunit) (eg,spinocerebellar ataxia),evaluation to detect abnormal(eg, expanded) alleles

CBFB/MYH11 (inv(16)) (eg,acute myeloid leukemia),qualitative, and quantitative, ifperformed

CBS (cystathionine-beta-synthase) (eg, homocystinuria,cystathionine beta-synthasedeficiency), common variants(eg, I278T, G307S)

CCND1/IGH (BCL1/IgH,t(11;14)) (eg, mantle celllymphoma) translocationanalysis, major breakpoint,qualitative, and quantitative, ifperformed

CFH/ARMS2 (complementfactor H/age-relatedmaculopathy susceptibility 2)(eg, macular degeneration),common variants (eg, Y402H[CFH], A69S [ARMS2])

CNBP (CCHC-type zinc finger,nucleic acid binding protein)(eg, myotonic dystrophy type2), evaluation to detectabnormal (eg, expanded)alleles

CSTB (cystatin B [stefin B])(eg, Unverricht-Lundborgdisease), evaluation to detectabnormal (eg, expanded)alleles

CYP3A4 (cytochrome P450,family 3, subfamily A,polypeptide 4) (eg, drugmetabolism), common variants(eg, *2, *3, *4, *5, *6)

CYP3A5 (cytochrome P450,family 3, subfamily A,polypeptide 5) (eg, drugmetabolism), common variants(eg, *2, *3, *4, *5, *6)

DMPK (dystrophia myotonica-protein kinase) (eg, myotonicdystrophy, type 1), evaluationto detect abnormal (eg,expanded) alleles

E2A/PBX1 (t(1;19)) (eg, acutelymphocytic leukemia),

translocation analysis,qualitative, and quantitative, ifperformed

EML4/ALK (inv(2)) (eg, non-small cell lung cancer),translocation or inversionanalysis

ETV6/NTRK3 (t(12;15)) (eg,congenital/infantilefibrosarcoma), translocationanalysis, qualitative, andquantitative, if performed

ETV6/RUNX1 (t(12;21)) (eg,acute lymphocytic leukemia),translocation analysis,qualitative, and quantitative, ifperformed

EWSR1/ATF1 (t(12;22)) (eg,clear cell sarcoma),translocation analysis,qualitative, and quantitative, ifperformed

EWSR1/ERG (t(21;22)) (eg,Ewing sarcoma/peripheralneuroectodermal tumor),translocation analysis,qualitative, and quantitative, ifperformed

EWSR1/FLI1 (t(11;22)) (eg,Ewing sarcoma/peripheralneuroectodermal tumor),translocation analysis,qualitative, and quantitative, ifperformed

EWSR1/WT1 (t(11;22)) (eg,desmoplastic small round celltumor), translocation analysis,qualitative, and quantitative, ifperformed

F11 (coagulation factor XI) (eg,coagulation disorder), commonvariants (eg, E117X [Type II],F283L [Type III], IVS14del14,and IVS14+1G>A [Type I])

FGFR3 (fibroblast growthfactor receptor 3) (eg,achondroplasia,hypochondroplasia), commonvariants (eg, 1138G>A,1138G>C, 1620C>A,1620C>G)

FIP1L1/PDGFRA (del[4q12])(eg, imatinib-sensitive chroniceosinophilic leukemia),qualitative, and quantitative, ifperformed

FLG (filaggrin) (eg, icthyosisvulgaris), common variants(eg, R501X, 2282del4,R2447X, S3247X, 3702delG)

FOXO1/PAX3 (t(2;13)) (eg,alveolar rhabdomyosarcoma),translocation analysis,qualitative, and quantitative, ifperformed

FOXO1/PAX7 (t(1;13)) (eg,alveolar rhabdomyosarcoma),translocation analysis,qualitative, and quantitative, ifperformed

FUS/DDIT3 (t(12;16)) (eg,myxoid liposarcoma),translocation analysis,qualitative, and quantitative, ifperformed

FXN (frataxin) (eg, Friedreichataxia), evaluation to detectabnormal (expanded) alleles

GALC (galactosylceramidase)(eg, Krabbe disease), commonvariants (eg, c.857G>A, 30-kbdeletion)

GALT (galactose-1-phosphateuridylyltransferase) (eg,galactosemia), commonvariants (eg, Q188R, S135L,K285N, T138M, L195P,Y209C, IVS2-2A>G, P171S,del5kb, N314D, L218L/N314D)

H19 (imprinted maternallyexpressed transcript [non-protein coding]) (eg, Beckwith-Wiedemann syndrome),methylation analysis

HBB (hemoglobin, beta) (eg,sickle cell anemia, hemoglobinC, hemoglobin E), commonvariants (eg, HbS, HbC, HbE)

HTT (huntingtin) (eg,Huntington disease),evaluation to detect abnormal(eg, expanded) alleles

KCNQ1OT1 (KCNQ1overlapping transcript 1 [non-protein coding]) (eg, Beckwith-Wiedemann syndrome),methylation analysis

LRRK2 (leucine-rich repeatkinase 2) (eg, Parkinsondisease), common variants(eg, R1441G, G2019S,I2020T)

MED12 (mediator complexsubunit 12) (eg, FG syndrometype 1, Lujan syndrome),common variants (eg, R961W,N1007S)

MEG3/DLK1 (maternallyexpressed 3 [non-proteincoding]/delta-like 1 homolog[Drosophila]) (eg, intrauterinegrowth retardation),methylation analysis

MLL/AFF1 (t(4;11)) (eg, acutelymphoblastic leukemia),translocation analysis,qualitative, and quantitative, ifperformed

MLL/MLLT3 (t(9;11)) (eg, acutemyeloid leukemia),translocation analysis,qualitative, and quantitative, ifperformed

MT-RNR1 (mitochondriallyencoded 12S RNA) (eg,nonsyndromic hearing loss),common variants (eg,m.1555A>G, m.1494C>T)

MUTYH (mutY homolog [E.coli]) (eg, MYH-associatedpolyposis), common variants(eg, Y165C, G382D)

MT-ATP6 (mitochondriallyencoded ATP synthase 6) (eg,neuropathy with ataxia andretinitis pigmentosa [NARP],Leigh syndrome), commonvariants (eg, m.8993T>G,m.8993T>C)

MT-ND4, MT-ND6(mitochondrially encodedNADH dehydrogenase 4,mitochondrially encodedNADH dehydrogenase 6) (eg,Leber hereditary opticneuropathy [LHON]), commonvariants (eg, m.11778G>A,m.3460G>A, m.14484T>C)

MT-TK (mitochondriallyencoded tRNA lysine) (eg,myoclonic epilepsy withragged-red fibers [MERRF]),common variants (eg,m.8344A>G, m.8356T>C)

MT-TL1 (mitochondriallyencoded tRNA leucine 1[UUA/G]) (eg, diabetes andhearing loss), commonvariants (eg, m.3243A>G,m.14709 T>C) MT-TL1

MT-ND5 (mitochondriallyencoded tRNA leucine 1[UUA/G], mitochondriallyencoded NADHdehydrogenase 5) (eg,mitochondrial encephalopathywith lactic acidosis and stroke-like episodes [MELAS]),common variants (eg,m.3243A>G, m.3271T>C,m.3252A>G, m.13513G>A)

MT-TS1, MT-RNR1(mitochondrially encoded tRNAserine 1 [UCN],mitochondrially encoded 12SRNA) (eg, nonsyndromicsensorineural deafness[including aminoglycoside-induced nonsyndromicdeafness]), common variants(eg, m.7445A>G, m.1555A>G)

NOD2 (nucleotide-bindingoligomerization domaincontaining 2) (eg, Crohn'sdisease, Blau syndrome),common variants (eg, SNP 8,SNP 12, SNP 13)

NPM1/ALK (t(2;5)) (eg,anaplastic large celllymphoma), translocationanalysis

PABPN1 (poly[A] bindingprotein, nuclear 1) (eg,oculopharyngeal musculardystrophy), evaluation todetect abnormal (eg,expanded) alleles

PAX8/PPARG (t(2;3)(q13;p25)) (eg, follicularthyroid carcinoma),translocation analysis

PPP2R2B (proteinphosphatase 2, regulatorysubunit B, beta) (eg,spinocerebellar ataxia),evaluation to detect abnormal(eg, expanded) alleles

PRSS1 (protease, serine, 1[trypsin 1]) (eg, hereditarypancreatitis), common variants(eg, N29I, A16V, R122H)

PYGM (phosphorylase,glycogen, muscle) (eg,glycogen storage disease typeV, McArdle disease), commonvariants (eg, R50X, G205S)

RUNX1/RUNX1T1 (t(8;21))(eg, acute myeloid leukemia)

translocation analysis,qualitative, and quantitative, ifperformed

SEPT9 (septin 9) (eg, coloncancer), methylation analysis

SMN1/SMN2 (survival ofmotor neuron 1,telomeric/survival of motorneuron 2, centromeric) (eg,spinal muscular atrophy),dosage analysis (eg, carriertesting)

(For duplication/deletionanalysis of SMN1/SMN2, use81401)

SS18/SSX1 (t(X;18)) (eg,synovial sarcoma),translocation analysis,qualitative, and quantitative, ifperformed

SS18/SSX2 (t(X;18)) (eg,synovial sarcoma),translocation analysis,qualitative, and quantitative, ifperformed

TBP (TATA box bindingprotein) (eg, spinocerebellarataxia), evaluation to detectabnormal (eg, expanded)alleles

TPMT (thiopurine S-methyltransferase) (eg, drugmetabolism), common variants(eg, *2, *3)

TYMS (thymidylatesynthetase) (eg, 5-fluorouracil/5-FU drugmetabolism), tandem repeatvariant

VWF (von Willebrand factor)(eg, von Willebrand diseasetype 2N), common variants(eg, T791M, R816W, R854Q)

81402 Molecular pathologyprocedure, Level 3 (eg, >10SNPs, 2-10 methylatedvariants, or 2-10 somaticvariants [typically using non-sequencing target variantanalysis], immunoglobulin andT-cell receptor generearrangements,duplication/deletion variants of1 exon, loss of heterozygosity[LOH], uniparental disomy[UPD])

Revised -- Molecular pathologyprocedure, Level 3 (eg,>10 SNPs, 2-10methylated variants, or 2-10 somatic variants[typically using non-sequencing target variantanalysis], immunoglobulinand T-cell receptor generearrangements,duplication/deletionvariants of 1 exon, loss ofheterozygosity [LOH],

CPT® 2016 revises81402, which representsall the technical work tocomplete just one specificmolecular test listed underthe code. The revisioninvolves deleting a listedtest for KIT (v-kit Hardy-Zuckerman 4 felinesarcoma viral oncogenehomolog) (e.g.,mastocytosis), commonvariants (e.g., D816V,

Chromosome 1p-/19q- (eg,glial tumors), deletion analysis

Chromosome 18q- (eg,D18S55, D18S58, D18S61,D18S64, and D18S69) (eg,colon cancer), allelicimbalance assessment (ie,loss of heterozygosity)

COL1A1/PDGFB (t(17;22))(eg, dermatofibrosarcomaprotuberans), translocationanalysis, multiple breakpoints,qualitative, and quantitative, ifperformed

CYP21A2 (cytochrome P450,family 21, subfamily A,polypeptide 2) (eg, congenitaladrenal hyperplasia, 21-hydroxylase deficiency),common variants (eg, IVS2-13G, P30L, I172N, exon 6mutation cluster [I235N,V236E, M238K], V281L,L307FfsX6, Q318X, R356W,P453S, G110VfsX21, 30-kbdeletion variant)

ESR1/PGR (receptor1/progesterone receptor) ratio(eg, breast cancer)

IGH@/BCL2 (t(14;18)) (eg,follicular lymphoma),translocation analysis; majorbreakpoint region (MBR) andminor cluster region (mcr)breakpoints, qualitative orquantitative

KIT (v-kit Hardy-Zuckerman 4feline sarcoma viral oncogenehomolog) (eg, mastocytosis),common variants (eg, D816V,D816Y, D816F)

MEFV (Mediterranean fever)(eg, familial Mediterraneanfever), common variants (eg,E148Q, P369S, F479L, M680I,I692del, M694V, M694I,K695R, V726A, A744S,R761H)

MPL (myeloproliferativeleukemia virus oncogene,thrombopoietin receptor,TPOR) (eg, myeloproliferativedisorder), common variants(eg, W515A, W515K, W515L,W515R)

TRD@ (T cell antigenreceptor, delta) (eg, leukemiaand lymphoma), gene

uniparental disomy [UPD])

KIT (v-kit Hardy-Zuckerman 4 felinesarcoma viral oncogenehomolog) (eg,mastocytosis), commonvariants (eg, D816V,D816Y, D816F)

D816Y, D816F). CPT®2016 adds a new Tier 1molecular pathology codefor this test: 81273 (KIT [v-kit Hardy-Zuckerman 4feline sarcoma viraloncogene homolog] [e.g.,mastocytosis], geneanalysis, D816 variant[s]).Each year, CPT® mayadd, delete, or revisesome tests listed undereach Tier 2 test level.

rearrangement analysis,evaluation to detect abnormalclonal population

Uniparental disomy (UPD) (eg,Russell-Silver syndrome,Prader-Willi/Angelmansyndrome), short tandemrepeat (STR) analysis

81403 Molecular pathologyprocedure, Level 4 (eg,analysis of single exon by DNAsequence analysis, analysis of>10 amplicons using multiplexPCR in 2 or more independentreactions, mutation scanningor duplication/deletion variantsof 2-5 exons)

ABL1 (c-abl oncogene 1,receptor tyrosine kinase) (eg,acquired imatinib tyrosinekinase inhibitor resistance),variants in the kinase domain

ANG (angiogenin,ribonuclease, RNase A family,5) (eg, amyotrophic lateralsclerosis), full gene sequence

ARX (aristaless-relatedhomeobox) (eg, X-linkedlissencephaly with ambiguousgenitalia, X-linked mentalretardation),duplication/deletion analysis

CEBPA (CCAAT/enhancerbinding protein [C/EBP], alpha)(eg, acute myeloid leukemia),full gene sequence

CEL (carboxyl ester lipase [bilesalt-stimulated lipase]) (eg,maturity-onset diabetes of theyoung [MODY]), targetedsequence analysis of exon 11(eg, c.1785delC, c.1686delT)

CTNNB1 (catenin [cadherin-associated protein], beta 1,88kDa) (eg, desmoid tumors),targeted sequence analysis(eg, exon 3)

DAZ/SRY (deleted inazoospermia and sexdetermining region Y) (eg,male infertility), commondeletions (eg, AZFa, AZFb,AZFc, AZFd)

DNMT3A (DNA [cytosine-5-]-methyltransferase 3 alpha)(eg, acute myeloid leukemia),

Revised -- Molecular pathologyprocedure, Level 4 (eg,analysis of single exon byDNA sequence analysis,analysis of >10 ampliconsusing multiplex PCR in 2or more independentreactions, mutationscanning orduplication/deletionvariants of 2-5 exons)

ABL1 (c-abl oncogene 1,receptor tyrosine kinase)(eg, acquired imatinibtyrosine kinase inhibitorresistance), variants in thekinase domain CEBPA(CCAAT/enhancer bindingprotein [C/EBP], alpha)(eg, acute myeloidleukemia), full genesequence KRAS (v-Ki-ras2Kirsten rat sarcoma viraloncogene) (eg,carcinoma), gene analysis,variant(s) in exon 3 (eg,codon 61)

CPT® 2016 revises81403, which representsall the technical work tocomplete just one specificmolecular test listed underthe code. The revisioninvolves deleting threetests that CPT® 2016 thenadds as new Tier 1molecular pathologycodes. The deleted testsare ABL1 (c-abl oncogene1, receptor tyrosinekinase) (e.g., acquiredimatinib tyrosine kinaseinhibitor resistance),variants in the kinasedomain, which becomesnew code 81170; CEBPA(CCAAT/enhancer bindingprotein [C/EBP], alpha)(e.g., acute myeloidleukemia), full genesequence, which becomesnew code 81218; andKRAS (v-Ki-ras2 Kirstenrat sarcoma viraloncogene) (e.g.,carcinoma), gene analysis,variant(s) in exon 3 (e.g.,codon 61) M, whichbecomes new code81276. Each year, CPT®may add, delete, or revisesome tests listed undereach Tier 2 test level.

targeted sequence analysis(eg, exon 23)

EPCAM (epithelial celladhesion molecule) (eg, Lynchsyndrome),duplication/deletion analysis

F8 (coagulation factor VIII) (eg,hemophilia A), inversionanalysis, intron 1 and intron22A

F12 (coagulation factor XII[Hageman factor]) (eg,angioedema, hereditary, typeIII; factor XII deficiency),targeted sequence analysis ofexon 9

FGFR3 (fibroblast growthfactor receptor 3) (eg, isolatedcraniosynostosis), targetedsequence analysis (eg, exon7)

(For targeted sequenceanalysis of multiple FGFR3exons, use 81404)

GJB1 (gap junction protein,beta 1) (eg, Charcot-Marie-Tooth X-linked), full genesequence

GNAQ (guanine nucleotide-binding protein G[q] subunitalpha) (eg, uveal melanoma),common variants (eg, R183,Q209)

HBB (hemoglobin, beta, beta-globin) (eg, beta thalassemia),duplication/deletion analysis

Human erythrocyte antigengene analyses (eg, SLC14A1[Kidd blood group], BCAM[Lutheran blood group], ICAM4[Landsteiner-Wiener bloodgroup], SLC4A1 [Diego bloodgroup], AQP1 [Colton bloodgroup], ERMAP [Sciannablood group], RHCE [Rh bloodgroup, CcEe antigens], KEL[Kell blood group], DARC[Duffy blood group], GYPA,GYPB, GYPE [MNS bloodgroup], ART4 [Dombrock bloodgroup]) (eg, sickle-celldisease, thalassemia,hemolytic transfusionreactions, hemolytic disease ofthe fetus or newborn), commonvariants

HRAS (v-Ha-ras Harvey rat

sarcoma viral oncogenehomolog) (eg, Costellosyndrome), exon 2 sequence

IDH1 (isocitratedehydrogenase 1 [NADP+],soluble) (eg, glioma), commonexon 4 variants (eg, R132H,R132C)

IDH2 (isocitratedehydrogenase 2 [NADP+],mitochondrial) (eg, glioma),common exon 4 variants (eg,R140W, R172M)

JAK2 (Janus kinase 2) (eg,myeloproliferative disorder),exon 12 sequence and exon13 sequence, if performed

Killer cell immunoglobulin-likereceptor (KIR) gene family (eg,hematopoietic stem celltransplantation), genotyping ofKIR family genes

Known familial variant nototherwise specified, for genelisted in Tier 1 or Tier 2, DNAsequence analysis, eachvariant exon

(For a known familial variantthat is considered a commonvariant, use specific commonvariant Tier 1 or Tier 2 code)

KCNC3 (potassium voltage-gated channel, Shaw-relatedsubfamily, member 3) (eg,spinocerebellar ataxia),targeted sequence analysis(eg, exon 2)

KCNJ2 (potassium inwardly-rectifying channel, subfamily J,member 2) (eg, Andersen-Tawil syndrome), full genesequence

KCNJ11 (potassium inwardly-rectifying channel, subfamily J,member 11) (eg, familialhyperinsulinism), full genesequence

KRAS (v-Ki-ras2 Kirsten ratsarcoma viral oncogene) (eg,carcinoma), gene analysis,variant(s) in exon 3 (eg, codon61)

MC4R (melanocortin 4receptor) (eg, obesity), fullgene sequence

MICA (MHC class Ipolypeptide-related sequenceA) (eg, solid organtransplantation), commonvariants (eg, *001, *002)

MPL (myeloproliferativeleukemia virus oncogene,thrombopoietin receptor,TPOR) (eg, myeloproliferativedisorder), exon 10 sequence

MT-RNR1 (mitochondriallyencoded 12S RNA) (eg,nonsyndromic hearing loss),full gene sequence

MT-TS1 (mitochondriallyencoded tRNA serine 1) (eg,nonsyndromic hearing loss),full gene sequence

NDP (Norrie disease[pseudoglioma]) (eg, Norriedisease), duplication/deletionanalysis

NHLRC1 (NHL repeatcontaining 1) (eg, progressivemyoclonus epilepsy), full genesequence

PHOX2B (paired-likehomeobox 2b) (eg, congenitalcentral hypoventilationsyndrome),duplication/deletion analysis

PLN (phospholamban) (eg,dilated cardiomyopathy,hypertrophic cardiomyopathy),full gene sequence

RHD (Rh blood group, Dantigen) (eg, hemolyticdisease of the fetus andnewborn, Rh maternal/fetalcompatibility), deletion analysis(eg, exons 4, 5, and 7,pseudogene)

RHD (Rh blood group, Dantigen) (eg, hemolyticdisease of the fetus andnewborn, Rh maternal/fetalcompatibility), deletion analysis(eg, exons 4, 5, and 7,pseudogene), performed oncell-free fetal DNA in maternalblood

(For human erythrocyte geneanalysis of RHD, use aseparate unit of 81403)

SH2D1A (SH2 domaincontaining 1A) (eg, X-linked

lymphoproliferative syndrome),duplication/deletion analysis

SMN1 (survival of motorneuron 1, telomeric) (eg, spinalmuscular atrophy), knownfamilial sequence variant(s)

TWIST1 (twist homolog 1[Drosophila]) (eg, Saethre-Chotzen syndrome),duplication/deletion analysis

UBA1 (ubiquitin-like modifieractivating enzyme 1) (eg,spinal muscular atrophy, X-linked), targeted sequenceanalysis (eg, exon 15)

VHL (von Hippel-Lindau tumorsuppressor) (eg, von Hippel-Lindau familial cancersyndrome),deletion/duplication analysis

VWF (von Willebrand factor)(eg, von Willebrand diseasetypes 2A, 2B, 2M), targetedsequence analysis (eg, exon28)81404 Molecular pathologyprocedure, Level 5 (eg,analysis of 2-5 exons by DNAsequence analysis, mutationscanning orduplication/deletion variants of6-10 exons, or characterizationof a dynamic mutationdisorder/triplet repeat bySouthern blot analysis)

ACADS (acyl-CoAdehydrogenase, C-2 to C-3short chain) (eg, short chainacyl-CoA dehydrogenasedeficiency), targeted sequenceanalysis (eg, exons 5 and 6)

AFF2 (AF4/FMR2 family,member 2 [FMR2]) (eg, fragileX mental retardation 2[FRAXE]), characterization ofalleles (eg, expanded size andmethylation status)

AQP2 (aquaporin 2 [collectingduct]) (eg, nephrogenicdiabetes insipidus), full genesequence

ARX (aristaless relatedhomeobox) (eg, X-linkedlissencephaly with ambiguousgenitalia, X-linked mentalretardation), full genesequence

AVPR2 (arginine vasopressin

Revised -- Molecular pathologyprocedure, Level 5 (eg,analysis of 2-5 exons byDNA sequence analysis,mutation scanning orduplication/deletionvariants of 6-10 exons, orcharacterization of adynamic mutationdisorder/triplet repeat bySouthern blot analysis)

KIT (C-kit) (v-kit Hardy-Zuckerman 4 felinesarcoma viral oncogenehomolog) (eg, GIST, acutemyeloid leukemia,melanoma), targeted geneanalysis (eg, exons 8, 11,13, 17, 18) NRAS(neuroblastoma RAS viraloncogene homolog) (eg,colorectal carcinoma),exon 1 and exon 2sequences PDGFRA(platelet-derived growthfactor receptor alphapolypeptide) (eg,gastrointestinal stromaltumor), targeted sequenceanalysis (eg, exons 12, 18)

CPT® 2016 revises81404, which representsall the technical work tocomplete just one specificmolecular test listed underthe code. The revisioninvolves deleting two teststhat CPT® 2016 then addsas new Tier 1 molecularpathology codes. Thedeleted tests are KIT (C-kit) (v-kit Hardy-Zuckerman 4 felinesarcoma viral oncogenehomolog) (e.g., GIST,acute myeloid leukemia,melanoma), targeted geneanalysis (e.g., exons 8, 11,13, 17, 18) L, whichbecomes new code81272; and NRAS(neuroblastoma RAS viraloncogene homolog) (e.g.,colorectal carcinoma),exon 1 and exon 2sequences PDGFRA(platelet-derived growthfactor receptor alphapolypeptide) (e.g.,gastrointestinal stromaltumor), targeted sequenceanalysis (e.g., exons 12,18) P, which becomes newcode 81311. Each year,CPT® may add, delete, orrevise some tests listedunder each Tier 2 test

receptor 2) (eg, nephrogenicdiabetes insipidus), full genesequence

BBS10 (Bardet-Biedlsyndrome 10) (eg, Bardet-Biedl syndrome), full genesequence

BTD (biotinidase) (eg,biotinidase deficiency), fullgene sequence

C10orf2 (chromosome 10open reading frame 2) (eg,mitochondrial DNA depletionsyndrome), full gene sequence

CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type1C), full gene sequence

CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome),full gene sequence

CDKN2A (cyclin-dependentkinase inhibitor 2A) (eg,CDKN2A-related cutaneousmalignant melanoma, familialatypical mole-malignantmelanoma syndrome), fullgene sequence

CLRN1 (clarin 1) (eg, Ushersyndrome, type 3), full genesequence

COX6B1 (cytochrome coxidase subunit VIbpolypeptide 1) (eg,mitochondrial respiratory chaincomplex IV deficiency), fullgene sequence

CPT2 (carnitinepalmitoyltransferase 2) (eg,carnitine palmitoyltransferaseII deficiency), full genesequence

CRX (cone-rod homeobox)(eg, cone-rod dystrophy 2,Leber congenital amaurosis),full gene sequence

CSTB (cystatin B [stefin B])(eg, Unverricht-Lundborgdisease), full gene sequence

CYP1B1 (cytochrome P450,family 1, subfamily B,polypeptide 1) (eg, primarycongenital glaucoma), fullgene sequence

level.

DMPK (dystrophia myotonica-protein kinase) (eg, myotonicdystrophy type 1),characterization of abnormal(eg, expanded) alleles

EGR2 (early growth response2) (eg, Charcot-Marie-Tooth),full gene sequence

EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy),duplication/deletion analysis

EPM2A (epilepsy, progressivemyoclonus type 2A, Laforadisease [laforin]) (eg,progressive myoclonusepilepsy), full gene sequence

FGF23 (fibroblast growthfactor 23) (eg,hypophosphatemic rickets), fullgene sequence

FGFR2 (fibroblast growthfactor receptor 2) (eg,craniosynostosis, Apertsyndrome, Crouzonsyndrome), targeted sequenceanalysis (eg, exons 8, 10)

FGFR3 (fibroblast growthfactor receptor 3) (eg,achondroplasia,hypochondroplasia), targetedsequence analysis (eg, exons8, 11, 12, 13)

FHL1 (four and a half LIMdomains 1) (eg, Emery-Dreifuss muscular dystrophy),full gene sequence

FKRP (fukutin related protein)(eg, congenital musculardystrophy type 1C [MDC1C],limb-girdle muscular dystrophy[LGMD] type 2I), full genesequence

FOXG1 (forkhead box G1) (eg,Rett syndrome), full genesequence

FSHMD1A(facioscapulohumeralmuscular dystrophy 1A) (eg,facioscapulohumeral musculardystrophy), evaluation todetect abnormal (eg, deleted)alleles

FSHMD1A(facioscapulohumeralmuscular dystrophy 1A) (eg,facioscapulohumeral muscular

dystrophy), characterization ofhaplotype(s) (ie, chromosome4A and 4B haplotypes)

FXN (frataxin) (eg, Friedreichataxia), full gene sequence

GH1 (growth hormone 1) (eg,growth hormone deficiency),full gene sequence

GP1BB (glycoprotein Ib[platelet], beta polypeptide)(eg, Bernard-Soulier syndrometype B), full gene sequence

HBA1/HBA2 (alpha globin 1and alpha globin 2) (eg, alphathalassemia),duplication/deletion analysis

(For common deletion variantsof alpha globin 1 and alphaglobin 2 genes, use 81257)

HBB (hemoglobin, beta, Beta-Globin) (eg, thalassemia), fullgene sequence

HNF1B (HNF1 homeobox B)(eg, maturity-onset diabetes ofthe young [MODY]),duplication/deletion analysis

HRAS (v-Ha-ras Harvey ratsarcoma viral oncogenehomolog) (eg, Costellosyndrome), full gene sequence

HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenasetype II deficiency), full genesequence

HSD11B2 (hydroxysteroid [11-beta] dehydrogenase 2) (eg,mineralocorticoid excesssyndrome), full gene sequence

HSPB1 (heat shock 27kDaprotein 1) (eg, Charcot-Marie-Tooth disease), full genesequence

INS (insulin) (eg, diabetesmellitus), full gene sequence

KCNJ1 (potassium inwardly-rectifying channel, subfamily J,member 1) (eg, Barttersyndrome), full gene sequence

KCNJ10 (potassium inwardly-rectifying channel, subfamily J,member 10) (eg, SeSAME

syndrome, EAST syndrome,sensorineural hearing loss),full gene sequence

KIT (C-kit) (v-kit Hardy-Zuckerman 4 feline sarcomaviral oncogene homolog) (eg,GIST, acute myeloid leukemia,melanoma), targeted geneanalysis (eg, exons 8, 11, 13,17, 18)

LITAF (lipopolysaccharide-induced TNF factor) (eg,Charcot-Marie-Tooth), fullgene sequence

MEFV (Mediterranean fever)(eg, familial Mediterraneanfever), full gene sequence

MEN1 (multiple endocrineneoplasia I) (eg, multipleendocrine neoplasia type 1,Wermer syndrome),duplication/deletion analysis

MMACHC (methylmalonicaciduria [cobalamin deficiency]cblC type, withhomocystinuria) (eg,methylmalonic acidemia andhomocystinuria), full genesequence

MPV17 (MpV17 mitochondrialinner membrane protein) (eg,mitochondrial DNA depletionsyndrome),duplication/deletion analysis

NDP (Norrie disease[pseudoglioma]) (eg, Norriedisease), full gene sequence

NDUFA1 (NADHdehydrogenase [ubiquinone] 1alpha subcomplex, 1, 7.5kDa)(eg, Leigh syndrome,mitochondrial complex Ideficiency), full genesequence

NDUFAF2 (NADHdehydrogenase [ubiquinone] 1alpha subcomplex, assemblyfactor 2) (eg, Leigh syndrome,mitochondrial complex Ideficiency), full genesequence

NDUFS4 (NADHdehydrogenase [ubiquinone]Fe-S protein 4, 18kDa [NADH-coenzyme Q reductase]) (eg,Leigh syndrome, mitochondrialcomplex I deficiency), full gene

sequence

NIPA1 (non-imprinted inPrader-Willi/Angelmansyndrome 1) (eg, spasticparaplegia), full genesequence

NLGN4X (neuroligin 4, X-linked) (eg, autism spectrumdisorders), duplication/deletionanalysis

NPC2 (Niemann-Pick disease,type C2 [epididymal secretoryprotein E1]) (eg, Niemann-Pickdisease type C2), full genesequence

NR0B1 (nuclear receptorsubfamily 0, group B, member1) (eg, congenital adrenalhypoplasia), full genesequence

NRAS (neuroblastoma RASviral oncogene homolog) (eg,colorectal carcinoma), exon 1and exon 2 sequences

PDGFRA (platelet-derivedgrowth factor receptor alphapolypeptide) (eg,gastrointestinal stromal tumor),targeted sequence analysis(eg, exons 12, 18)

PDX1 (pancreatic andduodenal homeobox 1) (eg,maturity-onset diabetes of theyoung [MODY]), full genesequence

PHOX2B (paired-likehomeobox 2b) (eg, congenitalcentral hypoventilationsyndrome), full gene sequence

PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase,catalytic subunit alpha) (eg,colorectal cancer), targetedsequence analysis (eg, exons9 and 20)

PLP1 (proteolipid protein 1)(eg, Pelizaeus-Merzbacherdisease, spastic paraplegia),duplication/deletion analysis

PQBP1 (polyglutamine bindingprotein 1) (eg, Renpenningsyndrome),duplication/deletion analysis

PRNP (prion protein) (eg,genetic prion disease), full

gene sequence

PROP1 (PROP paired-likehomeobox 1) (eg, combinedpituitary hormone deficiency),full gene sequence

PRPH2 (peripherin 2 [retinaldegeneration, slow]) (eg,retinitis pigmentosa), full genesequence

PRSS1 (protease, serine, 1[trypsin 1]) (eg, hereditarypancreatitis), full genesequence

RAF1 (v-raf-1 murine leukemiaviral oncogene homolog 1) (eg,LEOPARD syndrome),targeted sequence analysis(eg, exons 7, 12, 14, 17)

RET (ret proto-oncogene) (eg,multiple endocrine neoplasia,type 2B and familial medullarythyroid carcinoma), commonvariants (eg, M918T,2647_2648delinsTT, A883F)

RHO (rhodopsin) (eg, retinitispigmentosa), full genesequence

RP1 (retinitis pigmentosa 1)(eg, retinitis pigmentosa), fullgene sequence

SCN1B (sodium channel,voltage-gated, type I, beta)(eg, Brugada syndrome), fullgene sequence

SCO2 (SCO cytochromeoxidase deficient homolog 2[SCO1L]) (eg, mitochondrialrespiratory chain complex IVdeficiency), full genesequence

SDHC (succinatedehydrogenase complex,subunit C, integral membraneprotein, 15kDa) (eg, hereditaryparaganglioma-pheochromocytomasyndrome),duplication/deletion analysis

SDHD (succinatedehydrogenase complex,subunit D, integral membraneprotein) (eg, hereditaryparaganglioma), full genesequence

SGCG (sarcoglycan, gamma

[35kDa dystrophin-associatedglycoprotein]) (eg, limb-girdlemuscular dystrophy),duplication/deletion analysis

SH2D1A (SH2 domaincontaining 1A) (eg, X-linkedlymphoproliferative syndrome),full gene sequence

SLC16A2 (solute carrier family16, member 2 [thyroidhormone transporter]) (eg,specific thyroid hormone celltransporter deficiency, Allan-Herndon-Dudley syndrome),duplication/deletion analysis

SLC25A20 (solute carrierfamily 25[carnitine/acylcarnitinetranslocase], member 20) (eg,carnitine-acylcarnitinetranslocase deficiency),duplication/deletion analysis

SLC25A4 (solute carrier family25 [mitochondrial carrier;adenine nucleotidetranslocator], member 4) (eg,progressive externalophthalmoplegia), full genesequence

SOD1 (superoxide dismutase1, soluble) (eg, amyotrophiclateral sclerosis), full genesequence

SPINK1 (serine peptidaseinhibitor, Kazal type 1) (eg,hereditary pancreatitis), fullgene sequence

STK11 (serine/threoninekinase 11) (eg, Peutz-Jegherssyndrome),duplication/deletion analysis

TACO1 (translational activatorof mitochondrial encodedcytochrome c oxidase I) (eg,mitochondrial respiratory chaincomplex IV deficiency), fullgene sequence

THAP1 (THAP domaincontaining, apoptosisassociated protein 1) (eg,torsion dystonia), full genesequence

TOR1A (torsin family 1,member A [torsin A]) (eg,torsion dystonia), full genesequence

TP53 (tumor protein 53) (eg,tumor samples), targetedsequence analysis of 2-5exons

TTPA (tocopherol [alpha]transfer protein) (eg, ataxia),full gene sequence

TTR (transthyretin) (eg, familialtransthyretin amyloidosis), fullgene sequence

TWIST1 (twist homolog 1[Drosophila]) (eg, Saethre-Chotzen syndrome), full genesequence

TYR (tyrosinase[oculocutaneous albinism IA])(eg, oculocutaneous albinismIA), full gene sequence

USH1G (Usher syndrome 1G[autosomal recessive]) (eg,Usher syndrome, type 1), fullgene sequence

VHL (von Hippel-Lindau tumorsuppressor) (eg, von Hippel-Lindau familial cancersyndrome), full gene sequence

VWF (von Willebrand factor)(eg, von Willebrand diseasetype 1C), targeted sequenceanalysis (eg, exons 26, 27, 37)

ZEB2 (zinc finger E-boxbinding homeobox 2) (eg,Mowat-Wilson syndrome),duplication/deletion analysis

ZNF41 (zinc finger protein 41)(eg, X-linked mentalretardation 89), full genesequence

81405 Molecular pathologyprocedure, Level 6 (eg,analysis of 6-10 exons by DNAsequence analysis, mutationscanning orduplication/deletion variants of11-25 exons, regionallytargeted cytogenomic arrayanalysis)

ABCD1 (ATP-binding cassette,sub-family D [ALD], member 1)(eg, adrenoleukodystrophy),full gene sequence

ACADS (acyl-CoAdehydrogenase, C-2 to C-3short chain) (eg, short chainacyl-CoA dehydrogenasedeficiency), full genesequence

Revised -- Molecular pathologyprocedure, Level 6 (eg,analysis of 6-10 exons byDNA sequence analysis,mutation scanning orduplication/deletionvariants of 11-25 exons,regionally targetedcytogenomic arrayanalysis)

KRAS (v-Ki-ras2 Kirstenrat sarcoma viraloncogene homolog) (eg,Noonan syndrome), fullgene sequence

CPT® 2016 revises81405, which representsall the technical work tocomplete just one specificmolecular test listed underthe code. The revisioninvolves updating thename for a listed test forKRAS full sequenceanalysis from “v-Ki-ras2Kirsten rat sarcoma viraloncogene homolog” to“Kirsten rat sarcoma viraloncogene homolog,” butthe test remains under81405. Each year, CPT®may add, delete, or revisesome tests listed undereach Tier 2 test level.

ACTA2 (actin, alpha 2, smoothmuscle, aorta) (eg, thoracicaortic aneurysms and aorticdissections), full genesequence

ACTC1 (actin, alpha, cardiacmuscle 1) (eg, familialhypertrophic cardiomyopathy),full gene sequence

ANKRD1 (ankyrin repeatdomain 1) (eg, dilatedcardiomyopathy), full genesequence

APTX (aprataxin) (eg, ataxiawith oculomotor apraxia 1), fullgene sequence

AR (androgen receptor) (eg,androgen insensitivitysyndrome), full gene sequence

ARSA (arylsulfatase A) (eg,arylsulfatase A deficiency), fullgene sequence

BCKDHA (branched chain ketoacid dehydrogenase E1, alphapolypeptide) (eg, maple syrupurine disease, type 1A), fullgene sequence

BCS1L (BCS1-like [S.cerevisiae]) (eg, Leighsyndrome, mitochondrialcomplex III deficiency,GRACILE syndrome), full genesequence

BMPR2 (bone morphogeneticprotein receptor, type II[serine/threonine kinase]) (eg,heritable pulmonary arterialhypertension),duplication/deletion analysis

CASQ2 (calsequestrin 2[cardiac muscle]) (eg,catecholaminergic polymorphicventricular tachycardia), fullgene sequence

CASR (calcium-sensingreceptor) (eg, hypocalcemia),full gene sequence

CDKL5 (cyclin-dependentkinase-like 5) (eg, earlyinfantile epilepticencephalopathy),duplication/deletion analysisCHRNA4 (cholinergic receptor,nicotinic, alpha 4) (eg,nocturnal frontal lobeepilepsy), full gene sequence

CHRNB2 (cholinergic receptor,nicotinic, beta 2 [neuronal])(eg, nocturnal frontal lobeepilepsy), full gene sequence

COX10 (COX10 homolog,cytochrome c oxidaseassembly protein) (eg,mitochondrial respiratory chaincomplex IV deficiency), fullgene sequence

COX15 (COX15 homolog,cytochrome c oxidaseassembly protein) (eg,mitochondrial respiratory chaincomplex IV deficiency), fullgene sequence

CYP11B1 (cytochrome P450,family 11, subfamily B,polypeptide 1) (eg, congenitaladrenal hyperplasia), full genesequence

CYP17A1 (cytochrome P450,family 17, subfamily A,polypeptide 1) (eg, congenitaladrenal hyperplasia), full genesequence

CYP21A2 (cytochrome P450,family 21, subfamily A,polypeptide2) (eg, steroid 21-hydroxylase isoform,congenital adrenalhyperplasia), full genesequence

Cytogenomic constitutionaltargeted microarray analysis ofchromosome 22q13 byinterrogation of genomicregions for copy number andsingle nucleotidepolymorphism (SNP) variantsfor chromosomal abnormalities

(When performing genome-wide cytogenomicconstitutional microarrayanalysis, see 81228, 81229)

(Do not report analyte-specificmolecular pathologyprocedures separately whenthe specific analytes areincluded as part of themicroarray analysis ofchromosome 22q13)

(Do not report 88271 whenperforming cytogenomicmicroarray analysis)

DBT (dihydrolipoamidebranched chain transacylase

E2) (eg, maple syrup urinedisease, type 2),duplication/deletion analysis

DCX (doublecortin) (eg, X-linked lissencephaly), full genesequence

DES (desmin) (eg, myofibrillarmyopathy), full gene sequence

DFNB59 (deafness, autosomalrecessive 59) (eg, autosomalrecessive nonsyndromichearing impairment), full genesequence

DGUOK (deoxyguanosinekinase) (eg, hepatocerebralmitochondrial DNA depletionsyndrome), full gene sequence

DHCR7 (7-dehydrocholesterolreductase) (eg, Smith-Lemli-Opitz syndrome), full genesequence

EIF2B2 (eukaryotic translationinitiation factor 2B, subunit 2beta, 39kDa) (eg,leukoencephalopathy withvanishing white matter), fullgene sequence

EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy),full gene sequence

ENG (endoglin) (eg, hereditaryhemorrhagic telangiectasia,type 1), duplication/deletionanalysis

EYA1 (eyes absent homolog 1[Drosophila]) (eg, branchio-oto-renal [BOR] spectrumdisorders), duplication/deletionanalysis

F9 (coagulation factor IX) (eg,hemophilia B), full genesequence

FGFR1 (fibroblast growthfactor receptor 1) (eg,Kallmann syndrome 2), fullgene sequence

FH (fumarate hydratase) (eg,fumarate hydratase deficiency,hereditary leiomyomatosis withrenal cell cancer), full genesequence

FKTN (fukutin) (eg, limb-girdlemuscular dystrophy [LGMD]type 2M or 2L), full gene

sequence

FTSJ1 (FtsJ RNAmethyltransferase homolog 1[E. coli]) (eg, X-linked mentalretardation 9),duplication/deletion analysis

GABRG2 (gamma-aminobutyric acid [GABA] Areceptor, gamma 2) (eg,generalized epilepsy withfebrile seizures), full genesequence

GCH1 (GTP cyclohydrolase 1)(eg, autosomal dominantdopa-responsive dystonia), fullgene sequence

GDAP1 (ganglioside-induceddifferentiation-associatedprotein 1) (eg, Charcot-Marie-Tooth disease), full genesequence

GFAP (glial fibrillary acidicprotein) (eg, Alexanderdisease), full gene sequence

GHR (growth hormonereceptor) (eg, Laronsyndrome), full gene sequence

GHRHR (growth hormonereleasing hormone receptor)(eg, growth hormonedeficiency), full genesequence

GLA (galactosidase, alpha)(eg, Fabry disease), full genesequence

HBA1/HBA2 (alpha globin 1and alpha globin 2) (eg,thalassemia), full genesequence

HNF1A (HNF1 homeobox A)(eg, maturity-onset diabetes ofthe young [MODY]), full genesequence

HNF1B (HNF1 homeobox B)(eg, maturity-onset diabetes ofthe young [MODY]), full genesequence

HTRA1 (HtrA serine peptidase1) (eg, macular degeneration),full gene sequence

IDS (iduronate 2-sulfatase)(eg, mucopolysacchridosis,type II), full gene sequence

IL2RG (interleukin 2 receptor,

gamma) (eg, X-linked severecombined immunodeficiency),full gene sequence

ISPD (isoprenoid synthasedomain containing) (eg,muscle-eye-brain disease,Walker-Warburg syndrome),full gene sequence

KRAS (v-Ki-ras2 Kirsten ratsarcoma viral oncogenehomolog) (eg, Noonansyndrome), full gene sequence

LAMP2 (lysosomal-associatedmembrane protein 2) (eg,Danon disease), full genesequence

LDLR (low density lipoproteinreceptor) (eg, familialhypercholesterolemia),duplication/deletion analysis

MEN1 (multiple endocrineneoplasia I) (eg, multipleendocrine neoplasia type 1,Wermer syndrome), full genesequence

MMAA (methylmalonic aciduria[cobalamine deficiency] type A)(eg, MMAA-relatedmethylmalonic acidemia), fullgene sequence

MMAB (methylmalonicaciduria [cobalaminedeficiency] type B) (eg,MMAA-related methylmalonicacidemia), full gene sequence

MPI (mannose phosphateisomerase) (eg, congenitaldisorder of glycosylation 1b),full gene sequence

MPV17 (MpV17 mitochondrialinner membrane protein) (eg,mitochondrial DNA depletionsyndrome), full gene sequenceMPZ (myelin protein zero) (eg,Charcot-Marie-Tooth), fullgene sequence

MTM1 (myotubularin 1) (eg, X-linked centronuclearmyopathy),duplication/deletion analysis

MYL2 (myosin, light chain 2,regulatory, cardiac, slow) (eg,familial hypertrophiccardiomyopathy), full genesequence

MYL3 (myosin, light chain 3,alkali, ventricular, skeletal,slow) (eg, familial hypertrophiccardiomyopathy), full genesequence

MYOT (myotilin) (eg, limb-girdle muscular dystrophy), fullgene sequence

NDUFS7 (NADHdehydrogenase [ubiquinone]Fe-S protein 7, 20kDa [NADH-coenzyme Q reductase]) (eg,Leigh syndrome, mitochondrialcomplex I deficiency), full genesequence

NDUFS8 (NADHdehydrogenase [ubiquinone]Fe-S protein 8, 23kDa [NADH-coenzyme Q reductase]) (eg,Leigh syndrome, mitochondrialcomplex I deficiency), full genesequence

NDUFV1 (NADHdehydrogenase [ubiquinone]flavoprotein 1, 51kDa) (eg,Leigh syndrome, mitochondrialcomplex I deficiency), full genesequence

NEFL (neurofilament, lightpolypeptide) (eg, Charcot-Marie-Tooth), full genesequence

NF2 (neurofibromin 2 [merlin])(eg, neurofibromatosis, type2), duplication/deletionanalysis

NLGN3 (neuroligin 3) (eg,autism spectrum disorders),full gene sequence

NLGN4X (neuroligin 4, X-linked) (eg, autism spectrumdisorders), full gene sequence

NPHP1 (nephronophthisis 1[juvenile]) (eg, Joubertsyndrome), deletion analysis,and duplication analysis, ifperformed

NPHS2 (nephrosis 2,idiopathic, steroid-resistant[podocin]) (eg, steroid-resistant nephrotic syndrome),full gene sequence

NSD1 (nuclear receptorbinding SET domain protein 1)(eg, Sotos syndrome),duplication/deletion analysis

OTC (ornithinecarbamoyltransferase) (eg,ornithine transcarbamylasedeficiency), full genesequence

PAFAH1B1 (platelet-activatingfactor acetylhydrolase 1b,regulatory subunit 1 [45kDa])(eg, lissencephaly, Miller-Dieker syndrome),duplication/deletion analysis

PARK2 (Parkinson protein 2,E3 ubiquitin protein ligase[parkin]) (eg, Parkinsondisease), duplication/deletionanalysis

PCCA (propionyl CoAcarboxylase, alphapolypeptide) (eg, propionicacidemia,

type 1), duplication/deletionanalysis PCDH19(protocadherin 19) (eg,epileptic encephalopathy), fullgene sequence

PDHA1 (pyruvatedehydrogenase [lipoamide]alpha 1) (eg, lactic acidosis),duplication/deletion analysis

PDHB (pyruvatedehydrogenase [lipoamide]beta) (eg, lactic acidosis), fullgene sequence

PINK1 (PTEN induced putativekinase 1) (eg, Parkinsondisease), full gene sequence

PLP1 (proteolipid protein 1)(eg, Pelizaeus-Merzbacherdisease, spastic paraplegia),full gene sequence

POU1F1 (POU class 1homeobox 1) (eg, combinedpituitary hormone deficiency),full gene sequence

PRX (periaxin) (eg, Charcot-Marie-Tooth disease), full genesequence

PQBP1 (polyglutamine bindingprotein 1) (eg, Renpenningsyndrome), full gene sequence

PSEN1 (presenilin 1) (eg,Alzheimer disease), full genesequence

RAB7A (RAB7A, member RAS

oncogene family) (eg, Charcot-Marie-Tooth disease), full genesequence

RAI1 (retinoic acid induced 1)(eg, Smith-Magenissyndrome), full gene sequence

REEP1 (receptor accessoryprotein 1) (eg, spasticparaplegia), full genesequence

RET (ret proto-oncogene) (eg,multiple endocrine neoplasia,type 2A and familial medullarythyroid carcinoma), targetedsequence analysis (eg, exons10, 11, 13-16)

RPS19 (ribosomal proteinS19) (eg, Diamond-Blackfananemia), full gene sequence

RRM2B (ribonucleotidereductase M2 B [TP53inducible]) (eg, mitochondrialDNA depletion), full genesequence

SCO1 (SCO cytochromeoxidase deficient homolog 1)(eg, mitochondrial respiratorychain complex IV deficiency),full gene sequence

SDHB (succinatedehydrogenase complex,subunit B, iron sulfur) (eg,hereditary paraganglioma), fullgene sequence

SDHC (succinatedehydrogenase complex,subunit C, integral membraneprotein, 15kDa) (eg, hereditaryparaganglioma-pheochromocytomasyndrome), full gene sequence

SGCA (sarcoglycan, alpha[50kDa dystrophin-associatedglycoprotein]) (eg, limb-girdlemuscular dystrophy), full genesequence

SGCB (sarcoglycan, beta[43kDa dystrophin-associatedglycoprotein]) (eg, limb-girdlemuscular dystrophy), full genesequence

SGCD (sarcoglycan, delta[35kDa dystrophin-associatedglycoprotein]) (eg, limb-girdlemuscular dystrophy), full genesequence

SGCE (sarcoglycan, epsilon)(eg, myoclonic dystonia),duplication/deletion analysisSGCG (sarcoglycan, gamma[35kDa dystrophin-associatedglycoprotein]) (eg, limb-girdlemuscular dystrophy), full genesequence

SHOC2 (soc-2 suppressor ofclear homolog) (eg, Noonan-like syndrome with looseanagen hair), full genesequence

SHOX (short staturehomeobox) (eg, Langermesomelic dysplasia), fullgene sequence

SIL1 (SIL1 homolog,endoplasmic reticulumchaperone [S. cerevisiae]) (eg,ataxia), full gene sequence

SLC2A1 (solute carrier family2 [facilitated glucosetransporter], member 1) (eg,glucose transporter type 1[GLUT 1] deficiencysyndrome), full gene sequence

SLC16A2 (solute carrier family16, member 2 [thyroidhormone transporter]) (eg,specific thyroid hormone celltransporter deficiency, Allan-Herndon-Dudley syndrome),full gene sequence

SLC22A5 (solute carrier family22 [organic cation/carnitinetransporter], member 5) (eg,systemic primary carnitinedeficiency), full genesequence

SLC25A20 (solute carrierfamily 25[carnitine/acylcarnitinetranslocase], member 20) (eg,carnitine-acylcarnitinetranslocase deficiency), fullgene sequence

SMAD4 (SMAD family member4) (eg, hemorrhagictelangiectasia syndrome,juvenile polyposis),duplication/deletion analysisSMN1 (survival of motorneuron 1, telomeric) (eg, spinalmuscular atrophy), full genesequence

SPAST (spastin) (eg, spasticparaplegia),

duplication/deletion analysis

SPG7 (spastic paraplegia 7[pure and complicatedautosomal recessive]) (eg,spastic paraplegia),duplication/deletion analysis

SPRED1 (sprouty-related,EVH1 domain containing 1)(eg, Legius syndrome), fullgene sequence

STAT3 (signal transducer andactivator of transcription 3[acute-phase response factor])(eg, autosomal dominanthyper-IgE syndrome), targetedsequence analysis (eg, exons12, 13, 14, 16, 17, 20, 21)

STK11 (serine/threoninekinase 11) (eg, Peutz-Jegherssyndrome), full gene sequence

SURF1 (surfeit 1) (eg,mitochondrial respiratory chaincomplex IV deficiency), fullgene sequence

TARDBP (TAR DNA bindingprotein) (eg, amyotrophiclateral sclerosis), full genesequence

TBX5 (T-box 5) (eg, Holt-Oramsyndrome), full gene sequence

TCF4 (transcription factor 4)(eg, Pitt-Hopkins syndrome),duplication/deletion analysis

TGFBR1 (transforming growthfactor, beta receptor 1) (eg,Marfan syndrome), full genesequence

TGFBR2 (transforming growthfactor, beta receptor 2) (eg,Marfan syndrome), full genesequence

THRB (thyroid hormonereceptor, beta) (eg, thyroidhormone resistance, thyroidhormone beta receptordeficiency), full gene sequenceor targeted sequence analysisof >5 exons

TK2 (thymidine kinase 2,mitochondrial) (eg,mitochondrial DNA depletionsyndrome), full gene sequenceTNNC1 (troponin C type 1[slow]) (eg, hypertrophiccardiomyopathy or dilated

cardiomyopathy), full genesequence

TNNI3 (troponin I, type 3[cardiac]) (eg, familialhypertrophic cardiomyopathy),full gene sequence

TP53 (tumor protein 53) (eg,Li-Fraumeni syndrome, tumorsamples), full gene sequenceor targeted sequence analysisof >5 exons

TPM1 (tropomyosin 1 [alpha])(eg, familial hypertrophiccardiomyopathy), full genesequence

TSC1 (tuberous sclerosis 1)(eg, tuberous sclerosis),duplication/deletion analysisTYMP (thymidinephosphorylase) (eg,mitochondrial DNA depletionsyndrome), full gene sequence

VWF (von Willebrand factor)(eg, von Willebrand diseasetype 2N), targeted sequenceanalysis (eg, exons 18-20, 23-25)

WT1 (Wilms tumor 1) (eg,Denys-Drash syndrome,familial Wilms tumor), full genesequence

ZEB2 (zinc finger E-boxbinding homeobox 2) (eg,Mowat-Wilson syndrome), fullgene sequence

81406 Molecular pathologyprocedure, Level 7 (eg,analysis of 11-25 exons byDNA sequence analysis,mutation scanning orduplication/deletion variants of26-50 exons, cytogenomicarray analysis for neoplasia)

ACADVL (acyl-CoAdehydrogenase, very longchain) (eg, very long chainacyl-coenzyme Adehydrogenase deficiency),full gene sequence

ACTN4 (actinin, alpha 4) (eg,focal segmentalglomerulosclerosis), full genesequence

AFG3L2 (AFG3 ATPase familygene 3-like 2 [S. cerevisiae])(eg, spinocerebellar ataxia),full gene sequence

Revised -- Molecular pathologyprocedure, Level 7 (eg,analysis of 11-25 exons byDNA sequence analysis,mutation scanning orduplication/deletionvariants of 26-50 exons,cytogenomic arrayanalysis for neoplasia)

BRAF (vB-raf murinesarcoma viral Rafproto-oncogene homologB1, serine/threoninekinase) (eg, Noonansyndrome), full genesequence

PCSK9 (proproteinconvertase subtilisin/kexintype 9) (eg, familialhypercholesterolemia), fullgene sequence

CPT® 2016 revises81406, which representsall the technical work tocomplete just one specificmolecular test listed underthe code. The revisioninvolves adding a listedtest and updating thename of another test.CPT® 2016 adds PCSK9(proprotein convertasesubtilisin/kexin type 9)(e.g., familialhypercholesterolemia), fullgene sequence, andcorrects the name of theBRAF test from BRAF (v-raf murine sarcoma viraloncogene homolog B1) to(B-Raf proto-oncogenehomolog B1) (e.g.,Noonan syndrome), fullgene sequence, whichdoesn’t change how youreport the test. Each year,

AIRE (autoimmune regulator)(eg, autoimmunepolyendocrinopathy syndrometype 1), full gene sequence

ALDH7A1 (aldehydedehydrogenase 7 family,member A1) (eg, pyridoxine-dependent epilepsy), full genesequence

ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), fullgene sequence

APP (amyloid beta [A4]precursor protein) (eg,Alzheimer disease), full genesequence

ASS1 (argininosuccinatesynthase 1) (eg, citrullinemiatype I), full gene sequence

ATL1 (atlastin GTPase 1) (eg,spastic paraplegia), full genesequence

ATP1A2 (ATPase, Na+/K+transporting, alpha 2polypeptide) (eg, familialhemiplegic migraine), full genesequence

ATP7B (ATPase, Cu++transporting, beta polypeptide)(eg, Wilson disease), full genesequence

BBS1 (Bardet-Biedl syndrome1) (eg, Bardet-Biedlsyndrome), full gene sequence

BBS2 (Bardet-Biedl syndrome2) (eg, Bardet-Biedlsyndrome), full gene sequence

BCKDHB (branched-chainketo acid dehydrogenase E1,beta polypeptide) (eg, maplesyrup urine disease, type 1B),full gene sequence

BEST1 (bestrophin 1) (eg,vitelliform macular dystrophy),full gene sequence

BMPR2 (bone morphogeneticprotein receptor, type II[serine/threonine kinase]) (eg,heritable pulmonary arterialhypertension), full genesequence

BRAF (v-raf murine sarcomaviral oncogene homolog B1)(eg, Noonan syndrome), full

CPT® may add, delete, orrevise some tests listedunder each Tier 2 testlevel.

gene sequence

BSCL2 (Berardinelli-Seipcongenital lipodystrophy 2[seipin]) (eg, Berardinelli-Seipcongenital lipodystrophy), fullgene sequence

BTK (Brutonagammaglobulinemia tyrosinekinase) (eg, X-linkedagammaglobulinemia), fullgene sequence

CACNB2 (calcium channel,voltage-dependent, beta 2subunit) (eg, Brugadasyndrome), full gene sequence

CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy[LGMD] type 2A,calpainopathy), full genesequence

CBS (cystathionine-beta-synthase) (eg, homocystinuria,cystathionine beta-synthasedeficiency), full gene sequence

CDH1 (cadherin 1, type 1, E-cadherin [epithelial]) (eg,hereditary diffuse gastriccancer), full gene sequence

CDKL5 (cyclin-dependentkinase-like 5) (eg, earlyinfantile epilepticencephalopathy), full genesequence

CLCN1 (chloride channel 1,skeletal muscle) (eg, myotoniacongenita), full gene sequence

CLCNKB (chloride channel,voltage-sensitive Kb) (eg,Bartter syndrome 3 and 4b),full gene sequence

CNTNAP2 (contactin-associated protein-like 2) (eg,Pitt-Hopkins-like syndrome 1),full gene sequence

COL6A2 (collagen, type VI,alpha 2) (eg, collagen type VI-related disorders),duplication/deletion analysis

CPT1A (carnitinepalmitoyltransferase 1A [liver])(eg, carnitinepalmitoyltransferase 1A[CPT1A] deficiency), full genesequence

CRB1 (crumbs homolog 1[Drosophila]) (eg, Lebercongenital amaurosis), fullgene sequence

CREBBP (CREB bindingprotein) (eg, Rubinstein-Taybisyndrome),duplication/deletion analysis

Cytogenomic microarrayanalysis, neoplasia (eg,interrogation of copy number,and loss-of-heterozygosity viasingle nucleotidepolymorphism [SNP]-basedcomparative genomichybridization [CGH] microarrayanalysis)

(Do not report analyte-specificmolecular pathologyprocedures separately whenthe specific analytes areincluded as part of thecytogenomic microarrayanalysis for neoplasia)

(Do not report 88271 whenperforming cytogenomicmicroarray analysis)

DBT (dihydrolipoamidebranched chain transacylaseE2) (eg, maple syrup urinedisease, type 2), full genesequence

DLAT (dihydrolipoamide S-acetyltransferase) (eg,pyruvate dehydrogenase E2deficiency), full gene sequence

DLD (dihydrolipoamidedehydrogenase) (eg, maplesyrup urine disease, type III),full gene sequence

DSC2 (desmocollin) (eg,arrhythmogenic rightventriculardysplasia/cardiomyopathy 11),full gene sequence

DSG2 (desmoglein 2) (eg,arrhythmogenic rightventriculardysplasia/cardiomyopathy 10),full gene sequence

DSP (desmoplakin) (eg,arrhythmogenic rightventriculardysplasia/cardiomyopathy 8),full gene sequence

EFHC1 (EF-hand domain [C-

terminal] containing 1) (eg,juvenile myoclonic epilepsy),full gene sequence

EIF2B3 (eukaryotic translationinitiation factor 2B, subunit 3gamma, 58kDa) (eg,leukoencephalopathy withvanishing white matter), fullgene sequence

EIF2B4 (eukaryotic translationinitiation factor 2B, subunit 4delta, 67kDa) (eg,leukoencephalopathy withvanishing white matter), fullgene sequence

EIF2B5 (eukaryotic translationinitiation factor 2B, subunit 5epsilon, 82kDa) (eg, childhoodataxia with central nervoussystemhypomyelination/vanishingwhite matter), full genesequence

ENG (endoglin) (eg, hereditaryhemorrhagic telangiectasia,type 1), full gene sequence

EYA1 (eyes absent homolog 1[Drosophila]) (eg, branchio-oto-renal [BOR] spectrumdisorders), full gene sequence

F8 (coagulation factor VIII) (eg,hemophilia A),duplication/deletion analysis

FAH (fumarylacetoacetatehydrolase[fumarylacetoacetase]) (eg,tyrosinemia, type 1), full genesequence

FASTKD2 (FAST kinasedomains 2) (eg, mitochondrialrespiratory chain complex IVdeficiency), full gene sequence

FIG4 (FIG4 homolog, SAC1lipid phosphatase domaincontaining [S. cerevisiae]) (eg,Charcot-Marie-Tooth disease),full gene sequence

FTSJ1 (FtsJ RNAmethyltransferase homolog 1[E. coli]) (eg, X-linked mentalretardation 9), full genesequence

FUS (fused in sarcoma) (eg,amyotrophic lateral sclerosis),full gene sequence

GAA (glucosidase, alpha; acid)(eg, glycogen storage diseasetype II [Pompe disease]), fullgene sequence

GALC (galactosylceramidase)(eg, Krabbe disease), full genesequence

GALT (galactose-1-phosphateuridylyltransferase) (eg,galactosemia), full genesequence

GARS (glycyl-tRNAsynthetase) (eg, Charcot-Marie-Tooth disease), full genesequence

GCDH (glutaryl-CoAdehydrogenase) (eg,glutaricacidemia type 1), fullgene sequence

GCK (glucokinase [hexokinase4]) (eg, maturity-onsetdiabetes of the young[MODY]), full gene sequence

GLUD1 (glutamatedehydrogenase 1) (eg, familialhyperinsulinism), full genesequence

GNE (glucosamine [UDP-N-acetyl]-2-epimerase/N-acetylmannosamine kinase)(eg, inclusion body myopathy 2[IBM2], Nonaka myopathy), fullgene sequence

GRN (granulin) (eg,frontotemporal dementia), fullgene sequence

HADHA (hydroxyacyl-CoAdehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoAhydratase [trifunctional protein]alpha subunit) (eg, long chainacyl-coenzyme Adehydrogenase deficiency),full gene sequence

HADHB (hydroxyacyl-CoAdehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoAhydratase [trifunctionalprotein], beta subunit) (eg,trifunctional proteindeficiency), full gene sequence

HEXA (hexosaminidase A,alpha polypeptide) (eg, Tay-Sachs disease), full genesequence

HLCS (HLCS holocarboxylasesynthetase) (eg,holocarboxylase synthetasedeficiency), full gene sequence

HNF4A (hepatocyte nuclearfactor 4, alpha) (eg, maturity-onset diabetes of the young[MODY]), full gene sequence

IDUA (iduronidase, alpha-L-)(eg, mucopolysaccharidosistype I), full gene sequence

INF2 (inverted formin, FH2 andWH2 domain containing) (eg,focal segmentalglomerulosclerosis), full genesequence

IVD (isovaleryl-CoAdehydrogenase) (eg, isovalericacidemia), full gene sequence

JAG1 (jagged 1) (eg, Alagillesyndrome),duplication/deletion analysis

JUP (junction plakoglobin) (eg,arrhythmogenic rightventriculardysplasia/cardiomyopathy 11),full gene sequence

KAL1 (Kallmann syndrome 1sequence) (eg, Kallmannsyndrome), full gene sequence

KCNH2 (potassium voltage-gated channel, subfamily H[eag-related], member 2) (eg,short QT syndrome, long QTsyndrome), full gene sequence

(Do not report 81406 forKCNH2 full gene sequence inconjunction with 81280)

KCNQ1 (potassium voltage-gated channel, KQT-likesubfamily, member 1) (eg,short QT syndrome, long QTsyndrome), full gene sequence

(Do not report 81406 forKCNQ1 full gene sequencewith 81280)

KCNQ2 (potassium voltage-gated channel, KQT-likesubfamily, member 2) (eg,epileptic encephalopathy), fullgene sequence

LDB3 (LIM domain binding 3)(eg, familial dilatedcardiomyopathy, myofibrillar

myopathy), full gene sequence

LDLR (low density lipoproteinreceptor) (eg, familialhypercholesterolemia), fullgene sequence

LEPR (leptin receptor) (eg,obesity with hypogonadism),full gene sequence

LHCGR (luteinizinghormone/choriogonadotropinreceptor) (eg, precocious malepuberty), full gene sequence

LMNA (lamin A/C) (eg, Emery-Dreifuss muscular dystrophy[EDMD1, 2 and 3] limb-girdlemuscular dystrophy [LGMD]type 1B, dilatedcardiomyopathy [CMD1A],familial partial lipodystrophy[FPLD2]), full gene sequence

LRP5 (low density lipoproteinreceptor-related protein 5) (eg,osteopetrosis), full genesequence

MAP2K1 (mitogen-activatedprotein kinase 1) (eg,cardiofaciocutaneoussyndrome), full gene sequence

MAP2K2 (mitogen-activatedprotein kinase 2) (eg,cardiofaciocutaneoussyndrome), full gene sequence

MAPT (microtubule-associatedprotein tau) (eg,frontotemporal dementia), fullgene sequence

MCCC1 (methylcrotonoyl-CoAcarboxylase 1 [alpha]) (eg, 3-methylcrotonyl-CoAcarboxylase deficiency), fullgene sequence

MCCC2 (methylcrotonoyl-CoAcarboxylase 2 [beta]) (eg, 3-methylcrotonyl carboxylasedeficiency), full gene sequence

MFN2 (mitofusin 2) (eg,Charcot-Marie-Tooth disease),full gene sequence

MTM1 (myotubularin 1) (eg, X-linked centronuclearmyopathy), full gene sequence

MUT (methylmalonyl CoAmutase) (eg, methylmalonicacidemia), full gene sequence

MUTYH (mutY homolog [E.coli]) (eg, MYH-associatedpolyposis), full gene sequence

NDUFS1 (NADHdehydrogenase [ubiquinone]Fe-S protein 1, 75kDa [NADH-coenzyme Q reductase]) (eg,Leigh syndrome, mitochondrialcomplex I deficiency), full genesequence

NF2 (neurofibromin 2 [merlin])(eg, neurofibromatosis, type2), full gene sequence

NOTCH3 (notch 3) (eg,cerebral autosomal dominantarteriopathy with subcorticalinfarcts andleukoencephalopathy[CADASIL]), targetedsequence analysis (eg, exons1-23)

NPC1 (Niemann-Pick disease,type C1) (eg, Niemann-Pickdisease), full gene sequence

NPHP1 (nephronophthisis 1[juvenile]) (eg, Joubertsyndrome), full gene sequence

NSD1 (nuclear receptorbinding SET domain protein 1)(eg, Sotos syndrome), fullgene sequence

OPA1 (optic atrophy 1) (eg,optic atrophy),duplication/deletion analysis

OPTN (optineurin) (eg,amyotrophic lateral sclerosis),full gene sequence

PAFAH1B1 (platelet-activatingfactor acetylhydrolase 1b,regulatory subunit 1 [45kDa])(eg, lissencephaly, Miller-Dieker syndrome), full genesequence

PAH (phenylalaninehydroxylase) (eg,phenylketonuria), full genesequence

PALB2 (partner and localizer ofBRCA2) (eg, breast andpancreatic cancer), full genesequence

PARK2 (Parkinson protein 2,E3 ubiquitin protein ligase[parkin]) (eg, Parkinsondisease), full gene sequence

PAX2 (paired box 2) (eg, renalcoloboma syndrome), full genesequence

PC (pyruvate carboxylase) (eg,pyruvate carboxylasedeficiency), full gene sequence

PCCA (propionyl CoAcarboxylase, alphapolypeptide) (eg, propionicacidemia, type 1), full genesequence

PCCB (propionyl CoAcarboxylase, beta polypeptide)(eg, propionic acidemia), fullgene sequence

PCDH15 (protocadherin-related 15) (eg, Ushersyndrome type 1F),duplication/deletion analysis

PDHA1 (pyruvatedehydrogenase [lipoamide]alpha 1) (eg, lactic acidosis),full gene sequence

PDHX (pyruvatedehydrogenase complex,component X) (eg, lacticacidosis), full gene sequence

PHEX (phosphate-regulatingendopeptidase homolog, X-linked) (eg, hypophosphatemicrickets), full gene sequence

PKD2 (polycystic kidneydisease 2 [autosomaldominant]) (eg, polycystickidney disease), full genesequence

PKP2 (plakophilin 2) (eg,arrhythmogenic rightventriculardysplasia/cardiomyopathy 9),full gene sequence

PNKD (eg, paroxysmalnonkinesigenic dyskinesia)(eg, paroxysmalnonkinesigenic dyskinesia), fullgene sequence

POLG (polymerase [DNAdirected], gamma) (eg, Alpers-Huttenlocher syndrome,autosomal dominantprogressive externalophthalmoplegia), full genesequence

POMGNT1 (protein O-linkedmannose beta1,2-N

acetylglucosaminyltransferase)(eg, muscle-eye-brain disease,Walker-Warburg syndrome),full gene sequence

POMT1 (protein-O-mannosyltransferase 1) (eg,limb-girdle muscular dystrophy[LGMD] type 2K, Walker-Warburg syndrome), full genesequence

POMT2 (protein-O-mannosyltransferase 2) (eg,limb-girdle muscular dystrophy[LGMD] type 2N, Walker-Warburg syndrome), full genesequence

PRKAG2 (protein kinase,AMP-activated, gamma 2 non-catalytic subunit) (eg, familialhypertrophic cardiomyopathywith Wolff-Parkinson-Whitesyndrome, lethal congenitalglycogen storage disease ofheart), full gene sequence

PRKCG (protein kinase C,gamma) (eg, spinocerebellarataxia), full gene sequence

PSEN2 (presenilin 2[Alzheimer disease 4]) (eg,Alzheimer disease), full genesequence

PTPN11 (protein tyrosinephosphatase, non-receptortype 11) (eg, Noonansyndrome, LEOPARDsyndrome), full gene sequence

PYGM (phosphorylase,glycogen, muscle) (eg,glycogen storage disease typeV, McArdle disease), full genesequence

RAF1 (v-raf-1 murine leukemiaviral oncogene homolog 1) (eg,LEOPARD syndrome), fullgene sequence

RET (ret proto-oncogene) (eg,Hirschsprung disease), fullgene sequence

RPE65 (retinal pigmentepithelium-specific protein65kDa) (eg, retinitispigmentosa, Leber congenitalamaurosis), full genesequence

RYR1 (ryanodine receptor 1,skeletal) (eg, malignant

hyperthermia), targetedsequence analysis of exonswith functionally-confirmedmutations

SCN4A (sodium channel,voltage-gated, type IV, alphasubunit) (eg, hyperkalemicperiodic paralysis), full genesequence

SCNN1A (sodium channel,nonvoltage-gated 1 alpha) (eg,pseudohypoaldosteronism),full gene sequence

SCNN1B (sodium channel,nonvoltage-gated 1, beta) (eg,Liddle syndrome,pseudohypoaldosteronism),full gene sequence

SCNN1G (sodium channel,nonvoltage-gated 1, gamma)(eg, Liddle syndrome,pseudohypoaldosteronism),full gene sequence

SDHA (succinatedehydrogenase complex,subunit A, flavoprotein [Fp])(eg, Leigh syndrome,mitochondrial complex IIdeficiency), full gene sequence

SETX (senataxin) (eg, ataxia),full gene sequence

SGCE (sarcoglycan, epsilon)(eg, myoclonic dystonia), fullgene sequence

SH3TC2 (SH3 domain andtetratricopeptide repeats 2)(eg, Charcot-Marie-Toothdisease), full gene sequence

SLC9A6 (solute carrier family9 [sodium/hydrogenexchanger], member 6) (eg,Christianson syndrome), fullgene sequence

SLC26A4 (solute carrier family26, member 4) (eg, Pendredsyndrome), full gene sequence

SLC37A4 (solute carrier family37 [glucose-6-phosphatetransporter], member 4) (eg,glycogen storage disease typeIb), full gene sequence

SMAD4 (SMAD family member4) (eg, hemorrhagictelangiectasia syndrome,juvenile polyposis), full gene

sequence

SOS1 (son of sevenlesshomolog 1) (eg, Noonansyndrome, gingivalfibromatosis), full genesequence

SPAST (spastin) (eg, spasticparaplegia), full genesequence

SPG7 (spastic paraplegia 7[pure and complicatedautosomal recessive]) (eg,spastic paraplegia), full genesequence

STXBP1 (syntaxin-bindingprotein 1) (eg, epilepticencephalopathy), full genesequence

TAZ (tafazzin) (eg,methylglutaconic aciduria type2, Barth syndrome), full genesequence

TCF4 (transcription factor 4)(eg, Pitt-Hopkins syndrome),full gene sequence

TH (tyrosine hydroxylase) (eg,Segawa syndrome), full genesequence

TMEM43 (transmembraneprotein 43) (eg,arrhythmogenic rightventricular cardiomyopathy),full gene sequence

TNNT2 (troponin T, type 2[cardiac]) (eg, familialhypertrophic cardiomyopathy),full gene sequence

TRPC6 (transient receptorpotential cation channel,subfamily C, member 6) (eg,focal segmentalglomerulosclerosis), full genesequence

TSC1 (tuberous sclerosis 1)(eg, tuberous sclerosis), fullgene sequence

TSC2 (tuberous sclerosis 2)(eg, tuberous sclerosis),duplication/deletion analysis

UBE3A (ubiquitin proteinligase E3A) (eg, Angelmansyndrome), full gene sequence

UMOD (uromodulin) (eg,glomerulocystic kidney disease

with hyperuricemia andisosthenuria), full genesequence

VWF (von Willebrand factor)(von Willebrand disease type2A), extended targetedsequence analysis (eg, exons11-16, 24-26, 51, 52)

WAS (Wiskott-Aldrichsyndrome [eczema-thrombocytopenia]) (eg,Wiskott-Aldrich syndrome), fullgene sequence

81435 Hereditary colon cancersyndromes (eg, Lynchsyndrome, familialadenomatosis polyposis);genomic sequence analysispanel, must include analysis ofat least 7 genes, includingAPC, CHEK2, MLH1, MSH2,MSH6, MUTYH, and PMS2

Revised -- Hereditary colon cancersyndromesdisorders (eg,Lynch syndrome, PTENhamartoma syndrome,Cowden syndrome, familialadenomatosis polyposis);genomic sequenceanalysis panel, mustincludeanalysissequencing of atleast 710 genes, includingAPC, BMPR1A,CHEK2CDH1, MLH1,MSH2, MSH6, MUTYH,PTEN, SMAD4, andPMS2STK11

CPT® 2016 revises 81435for hereditary colon cancerdisorders by broadeningthe code from testing forLynch Syndrome andfamilial adenomatosispolyposis to also includePTEN hamartomasyndrome, Cowdensyndrome. The codedefinitions changes from apanel including analysis ofat least seven genes,including APC, CHEK2,MLH1, MSH2, MSH6,MUTYH, and PMS2, to apanel including analysis ofat least 10 genes,including APC, BMPR1A,CDH1, MLH1, MSH2,MSH6, MUTYH, PTEN,SMAD4, and STK11

81436 Hereditary colon cancersyndromes (eg, Lynchsyndrome, familialadenomatosis polyposis);duplication/deletion geneanalysis panel, must includeanalysis of at least 8 genes,including APC, MLH1, MSH2,MSH6, PMS2, EPCAM,CHEK2, and MUTYH

Revised -- duplication/deletion geneanalysis panel, mustinclude analysis of at least85 genes, including APC,MLH1, MSH2, MSH6,PMS2, EPCAM,CHEK2SMAD4, andMUTYHSTK11

CPT® 2016 revises 81436for hereditary colon cancerdisorders by broadeningthe code from testing forLynch Syndrome andfamilial adenomatosispolyposis to also includePTEN hamartomasyndrome, Cowdensyndrome. The codedefinitions changes from apanel includingduplication/deletionanalysis of at least eightgenes, including APC,MLH1, MSH2, MSH6,PMS2, EPCAM, CHEK2,and MUTYH, to a panelincluding duplicationdeletion analysis of at leastfive genes, includingMLH1, MSH2, EPCAM,SMAD4, and STK11.

81445 Targeted genomic sequenceanalysis panel, solid organneoplasm, DNA analysis, 5-50genes (eg, ALK, BRAF,CDKN2A, EGFR, ERBB2, KIT,KRAS, NRAS, MET, PDGFRA,PDGFRB, PGR, PIK3CA,PTEN, RET), interrogation forsequence variants and copynumber variants orrearrangements, if performed

Revised -- Targeted genomicsequence analysis panel,solid organ neoplasm,DNA analysis, and RNAanalysis when performed,5-50 genes (eg, ALK,BRAF, CDKN2A, EGFR,ERBB2, KIT, KRAS,NRAS, MET, PDGFRA,PDGFRB, PGR, PIK3CA,PTEN, RET), interrogationfor sequence variants andcopy number variants orrearrangements, ifperformed

CPT® 2016 revises 81445targeted genomicsequence analysis forsolid organ tumors toinclude RNA analysis, ifperformed. In 2015, thecode definition specifiedDNA analysis. Theaddition of “RNA” to thecode is a clarification, andshould not change the wayyou use this code.

81450 Targeted genomic sequenceanalysis panel,hematolymphoid neoplasm ordisorder, DNA and RNAanalysis when performed, 5-50genes (eg, BRAF, CEBPA,DNMT3A, EZH2, FLT3, IDH1,IDH2, JAK2, KRAS, KIT, MLL,NRAS, NPM1, NOTCH1),interrogation for sequencevariants, and copy numbervariants or rearrangements, orisoform expression or mRNAexpression levels, if performed

Revised -- Targeted genomicsequence analysis panel,hematolymphoid neoplasmor disorder, DNA analysis,and RNA analysis whenperformed, 5-50Â Â genes (eg, BRAF,CEBPA, DNMT3A, EZH2,FLT3, IDH1, IDH2, JAK2,KRAS, KIT, MLL, NRAS,NPM1, NOTCH1),interrogation for sequencevariants, and copy numbervariants orrearrangements, orisoform expression ormRNA expression levels, ifperformed

CPT® 2016 revises 81450targeted genomicsequence analysis forsolid organ tumors toinclude RNA analysis, ifperformed. In 2015, thecode definition specifiedDNA analysis. Theaddition of “RNA” to thecode is a clarification, andshould not change the wayyou use this code.

81455 Targeted genomic sequenceanalysis panel, solid organ orhematolymphoid neoplasm,DNA and RNA analysis whenperformed, 51 or greatergenes (eg, ALK, BRAF,CDKN2A, CEBPA, DNMT3A,EGFR, ERBB2, EZH2, FLT3,IDH1, IDH2, JAK2, KIT, KRAS,MLL, NPM1, NRAS, MET,NOTCH1, PDGFRA,PDGFRB, PGR, PIK3CA,PTEN, RET), interrogation forsequence variants and copynumber variants orrearrangements, if performed

Revised -- Targeted genomicsequence analysis panel,solid organ orhematolymphoidneoplasm, DNA analysis,and RNA analysis whenperformed, 51 or greatergenes (eg, ALK, BRAF,CDKN2A, CEBPA,DNMT3A, EGFR, ERBB2,EZH2, FLT3, IDH1, IDH2,JAK2, KIT, KRAS, MLL,NPM1, NRAS, MET,NOTCH1, PDGFRA,PDGFRB, PGR, PIK3CA,PTEN, RET), interrogationfor sequence variants andcopy number variants orrearrangements, ifperformed

CPT® 2016 revises 81455targeted genomicsequence analysis forsolid organ orhematolymphoidneoplasms with a minorwording change from“DNA and RNA analysis” to“DNA analysis, and RNAanalysis.” The revisiondoes not alter the meaningof the code, and shouldnot change the way youuse the code.

82486 Chromatography, qualitative;column (eg, gas liquid orHPLC), analyte not elsewherespecified

Deleted (82486 hasbeen deleted.For a qualitativecolumnchromatographyprocedure, usethe appropriatespecific analytecode, ifavailable, or82542)

CPT® 2016 deletes82486, which describesqualitative columnchromatography for ananalyte not specified inany other code. Examplesinclude gas liquidchromatography, calledGLC, or high performanceliquid chromatography,called HPLC. This deletionis part of an overallrevision of how you shouldreport columnchromatography and massspectrometry, or MS,procedures for unspecifiedanalytes. CPT® 2016deletes all codes in therange 82846 to 83789,except for revised codes82542 and 83789. Therevised codes encompassall columnchromatography and MSprocedures for unspecifiedanalytes, but adds thedistinction that you canuse the codes only forunspecified nondruganalytes. Crosswalk your82486 tests for nondruganalytes to 82542beginning in 2016.

82487 Chromatography, qualitative;paper, 1-dimensional, analytenot elsewhere specified

Deleted (82487, 82488have beendeleted. For apaperchromatographyprocedure, usethe appropriatespecific analytecode, ifavailable, or84999)

CPT® 2016 deletes82487, which describesone-dimensionalqualitative paperchromatography for ananalyte not specified inany other code. The codedescribes an older testmethod that labs rarelyperform. The 82487deletion is part of anoverall revision of how youshould reportchromatography and massspectrometry, or MS,procedures for unspecifiedanalytes. CPT® 2016deletes all codes in therange 82846 to 83789,except for revised codes82542 and 83789. Therevised codes encompassall columnchromatography and MSprocedures for unspecifiedanalytes, but adds thedistinction that you canuse the codes only forunspecified nondruganalytes. Because therevised chromatographycode 82542 does notinclude paperchromatography, youshould not crosswalk82487 to 82542 beginningin 2016, but must insteaduse an unlisted procedurecode such as 84999 in therare case that your labperforms this procedure.

82488 Chromatography, qualitative;paper, 2-dimensional, analytenot elsewhere specified

Deleted (82487, 82488have beendeleted. For apaperchromatographyprocedure, usethe appropriatespecific analytecode, ifavailable, or84999)

CPT® 2016 deletes82488, which describestwo-dimensionalqualitative paperchromatography for ananalyte not specified inany other code. The codedescribes an older testmethod that labs rarelyperform. The 82488deletion is part of anoverall revision of how youshould reportchromatography and massspectrometry, or MS,procedures for unspecifiedanalytes. CPT® 2016deletes all codes in therange 82846 to 83789,except for revised codes82542 and 83789. Therevised codes encompassall columnchromatography and MSprocedures for unspecifiedanalytes, but adds thedistinction that you canuse the codes only forunspecified nondruganalytes. Because therevised chromatographycode 82542 does notinclude paperchromatography, youshould not crosswalk82488 to 82542 beginningin 2016, but must insteaduse an unlisted procedurecode such as 84999 in therare case that your labperforms this procedure.

82489 Chromatography, qualitative;thin layer, analyte notelsewhere specified

Deleted (82489 hasbeen deleted.For a thin layerchromatographyprocedure, usethe appropriatespecific analytecode, ifavailable, or84999)

CPT® 2016 deletes82489, which describesqualitative thin layerchromatography, calledTLC, for an analyte notspecified in any othercode. The 82489 deletionis part of an overallrevision of how you shouldreport chromatographyand mass spectrometry, orMS, procedures forunspecified analytes.CPT® 2016 deletes allcodes in the range 82846to 83789, except forrevised codes 82542 and83789. The revised codesencompass all columnchromatography and MSprocedures for unspecifiedanalytes, but adds thedistinction that you canuse the codes only forunspecified nondruganalytes. Because therevised chromatographycode 82542 does notinclude TLC, you shouldnot crosswalk 82488 to82542 beginning in 2016,but must instead use anunlisted procedure codesuch as 84999 if your labperforms this procedure.

82491 Chromatography, quantitative,column (eg, gas liquid orHPLC); single analyte notelsewhere specified, singlestationary and mobile phase

Deleted (82491 hasbeen deleted.For aquantitativecolumnchromatographyprocedure, usethe appropriatespecific analytecode, ifavailable, or82542)

CPT® 2016 deletes82491, which describesquantitative columnchromatography for asingle analyte notspecified in any othercode. Examples includegas liquid chromatography,called GLC, or highperformance liquidchromatography, calledHPLC. This deletion is partof an overall revision ofhow you should reportcolumn chromatographyand mass spectrometry, orMS, procedures forunspecified analytes.CPT® 2016 deletes allcodes in the range 82846to 83789, except forrevised codes 82542 and83789. The revised codesencompass all columnchromatography and MSprocedures for unspecifiedanalytes, but adds thedistinction that you canuse the codes only forunspecified nondruganalytes. Crosswalk your82491 tests for nondruganalytes to 82542beginning in 2016.

82492 Chromatography, quantitative,column (eg, gas liquid orHPLC); multiple analytes,single stationary and mobilephase

Deleted (82492 hasbeen deleted.For aquantitativecolumnchromatographyprocedure thatdetects morethan oneanalyte, use asingle specificcode thatrepresents all ofthe analytes, ifavailable, orone unit of82542 for all ofthe analytes)

CPT® 2016 deletes82492, which describesquantitative columnchromatography formultiple analytes notspecified in any othercode. Examples includegas liquid chromatography,called GLC, or highperformance liquidchromatography, calledHPLC. This deletion is partof an overall revision ofhow you should reportcolumn chromatographyand mass spectrometry, orMS, procedures forunspecified analytes.CPT® 2016 deletes allcodes in the range 82846to 83789, except forrevised codes 82542 and83789. The revised codesencompass all columnchromatography and MSprocedures for unspecifiedanalytes, but adds thedistinction that you canuse the codes only forunspecified nondruganalytes. Crosswalk your82492 tests for nondruganalytes to 82542beginning in 2016.

82541 Column chromatography/massspectrometry (eg, GC/MS, orHPLC/MS), non-drug analytenot elsewhere specified;qualitative, single stationaryand mobile phase

Deleted (82541 hasbeen deleted.For aquantitativechromatographyprocedure withmassspectrometrythat only detectsa single specificanalyte, use theappropriatespecific analytecode, ifapplicable, or82542)

CPT® 2016 deletes82541, which describesqualitative columnchromatography and massspectrometry, called MS,for an analyte not specifiedin any other code.Examples include gaschromatography with MS,called GC/MS, or highperformance liquidchromatography with MS,called HPLC/MS. Thisdeletion is part of anoverall revision of how youshould report columnchromatography and massspectrometry proceduresfor unspecified analytes.CPT® 2016 deletes allcodes in the range 82846to 83789, except forrevised codes 82542 and83789. The revised codesencompass all columnchromatography and MSprocedures for unspecifiedanalytes, and makes thedistinction that you canuse the codes only forunspecified nondruganalytes. Crosswalk your82541 tests for nondruganalytes to 82542beginning in 2016.

82542 Column chromatography/massspectrometry (eg, GC/MS, orHPLC/MS), non-drug analytenot elsewhere specified;quantitative, single stationaryand mobile phase

Revised -- Column chromatography/,includes massspectrometry, if performed(eg, HPLC, LC, LC/MS,LC/MS-MS, GC,GC/MS-MS, orGC/MS,HPLC/MS), non-druganalyte(s) not elsewherespecified, qualitative orquantitative, eachspecimen; quantitative,single stationary andmobile phase

CPT® 2016 revises 82542and deletes all othercodes in the range 82846to 82544 so that,beginning in 2016, youshould report 82542 forany unlisted qualitative orquantitative non-drug testusing columnchromatography and massspectrometry, if performed.Types of testing includegas chromatography,called GC, liquidchromatography, calledLC, high performanceliquid chromatography,called HPLC, massspectrometry, called MS,and tandem massspectrometry, called MS-MS. The test may alsoinvolve combinationmethods such as LC/MS,LC/MS-MS, GC/MS,GC/MS-MS, or HPLC/MS.

82543 Column chromatography/massspectrometry (eg, GC/MS, orHPLC/MS), non-drug analytenot elsewhere specified; stableisotope dilution, single analyte,quantitative, single stationaryand mobile phase

Deleted (82543 hasbeen deleted.For aquantitativechromatographyprocedure withmassspectrometrythat only detectsa single specificanalyte, use theappropriatespecific analytecode, ifavailable, or82542)

CPT® 2016 deletes82543, which describesquantitative columnchromatography and massspectrometry, called MS,for a single analyte notspecified in any othercode. Examples includegas chromatography withMS, called GC/MS, or highperformance liquidchromatography with MS,called HPLC/MS. Thisdeletion is part of anoverall revision of how youshould report columnchromatography and massspectrometry proceduresfor unspecified analytes.CPT® 2016 deletes allcodes in the range 82846to 83789, except forrevised codes 82542 and83789. The revised codesencompass all columnchromatography and MSprocedures for unspecifiedanalytes, and makes thedistinction that you canuse the codes only forunspecified nondruganalytes. Crosswalk your82543 tests for nondruganalytes to 82542beginning in 2016.

82544 Column chromatography/massspectrometry (eg, GC/MS, orHPLC/MS), non-drug analytenot elsewhere specified; stableisotope dilution, multipleanalytes, quantitative, singlestationary and mobile phase

Deleted (82544 hasbeen deleted.For aquantitativechromatographyprocedure withmassspectrometrythat detectsmore than oneanalyte, use asingle specificcode thatrepresents all ofthe analytes, ifavailable, orone unit of82542 for all ofthe analytes)

CPT® 2016 deletes82544, which describesquantitative columnchromatography and massspectrometry, called MS,for multiple analytes notspecified in any othercode. Examples includegas chromatography withMS, called GC/MS, or highperformance liquidchromatography with MS,called HPLC/MS. Thisdeletion is part of anoverall revision of how youshould report columnchromatography and massspectrometry proceduresfor unspecified analytes.CPT® 2016 deletes allcodes in the range 82846to 83789, except forrevised codes 82542 and83789. The revised codesencompass all columnchromatography and MSprocedures for unspecifiedanalytes, and makes thedistinction that you canuse the codes only forunspecified nondruganalytes. Crosswalk your82544 tests for nondruganalytes to 82542beginning in 2016.

83788 Mass spectrometry andtandem mass spectrometry(MS, MS/MS), analyte notelsewhere specified;qualitative, each specimen

Deleted (83788 hasbeen deleted.For a qualitativemassspectrometry ortandem massspectrometryprocedure, usethe specificanalyte code, ifavailable, or83789)

CPT® 2016 deletes83788, which describesqualitative massspectrometry, called MS,or tandem massspectrometry, calledMS/MS, for an analyte notspecified in any othercode. This deletion is partof an overall revision ofhow you should reportcolumn chromatographyand mass spectrometryprocedures for unspecifiedanalytes. CPT® 2016deletes all codes in therange 82846 to 83789,except for revised codes82542 and 83789. Therevised codes encompassall columnchromatography and MSprocedures for unspecifiedanalytes, and makes thedistinction that you canuse the codes only forunspecified nondruganalytes. Crosswalk your83788 tests for nondruganalytes to 83789beginning in 2016.

83789 Mass spectrometry andtandem mass spectrometry(MS, MS/MS), analyte notelsewhere specified;quantitative, each specimen

Revised -- Mass spectrometry andtandem massspectrometry (eg, MS,MS/MS, MALDI, MS-TOF,QTOF), non-druganalyte(s) not elsewherespecified, qualitative orquantitative, eachspecimen; quantitative,each specimen

CPT® 2016 revises 83789to remove the“quantitative” restriction,and deletes 83788 forqualitative testing. Thatmeans that beginning in2016, you should report83789 for any unlistedqualitative or quantitativenon-drug test using massspectrometry. Types oftesting include massspectrometry, called MS,and tandem massspectrometry, calledMS/MS), which alsoincludes methods such asmatrix assisted laserdesorption/ionization(MALDI), massspectrometry time-of-flight(MS-TOF), or quadrupoletime-of-flight (QTOF).

86708 Hepatitis A antibody (HAAb);total

Revised -- Hepatitis A antibody(HAAb); total

CPT® 2016 revises code86708 to remove the word“total” from the descriptor,and to remove thesemicolon so that it is nolonger a parent code for86709. You shouldcontinue to report 86708for hepatitis A antibody(HAAb), except for the IgMclass, which you shouldreport using 86709.

86709 Hepatitis A antibody (HAAb);IgM antibody

Revised -- Hepatitis A antibody(HAAb), IgM antibody; IgMantibody

CPT® 2016 revises code86709 so that it is nolonger indented underparent code 86708. Youshould continue to use86709 as you always haveto report hepatitis A IgMantibody testing.

87301 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;adenovirus enteric types 40/41

Revised -- Infectious agent antigendetection by immunoassaytechnique, (eg, enzymeimmunoassaytechnique[EIA], enzyme-linked immunosorbentassay [ELISA],immunochemiluminometricassay [IMCA]) qualitativeor semiquantitative,multiple-step method;adenovirus enteric types40/41

CPT® 2016 revises thecommon part of the codedescriptor for 87301,which is a parent code for87305 to 87430, meaningthat the definition changesfor all codes in that range.The revision simply addsclarifying language to giveexamples of immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87305 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Aspergillus

Revised -- Aspergillus CPT® 2016 revises 87305as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87320 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Chlamydia trachomatis

Revised -- Chlamydia trachomatis CPT® 2016 revises 87320as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87324 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Clostridium difficile toxin(s)

Revised -- Clostridium difficile toxin(s) CPT® 2016 revises 87324as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87327 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Cryptococcus neoformans

Revised -- Cryptococcus neoformans CPT® 2016 revises 87327as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87328 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;cryptosporidium

Revised -- cryptosporidium CPT® 2016 revises 87328as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87329 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method; giardia

Revised -- giardia CPT® 2016 revises 87329as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87332 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;cytomegalovirus

Revised -- cytomegalovirus CPT® 2016 revises 87332as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87335 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Escherichia coli 0157

Revised -- Escherichia coli 0157 CPT® 2016 revises 87335as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87336 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Entamoeba histolytica dispargroup

Revised -- Entamoeba histolyticadispar group

CPT® 2016 revises 87336as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87337 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Entamoeba histolytica group

Revised -- Entamoeba histolyticagroup

CPT® 2016 revises 87337as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87338 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Helicobacter pylori, stool

Revised -- Helicobacter pylori, stool CPT® 2016 revises 87338as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87339 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Helicobacter pylori

Revised -- Helicobacter pylori CPT® 2016 revises 87339as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87340 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method; hepatitisB surface antigen (HBsAg)

Revised -- hepatitis B surface antigen(HBsAg)

CPT® 2016 revises 87340as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87341 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method; hepatitisB surface antigen (HBsAg)neutralization

Revised -- hepatitis B surface antigen(HBsAg) neutralization

CPT® 2016 revises 87341as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87350 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method; hepatitisBe antigen (HBeAg)

Revised -- hepatitis Be antigen(HBeAg)

CPT® 2016 revises 87350as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87380 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;hepatitis, delta agent

Revised -- hepatitis, delta agent CPT® 2016 revises 87380as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87385 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Histoplasma capsulatum

Revised -- Histoplasma capsulatum CPT® 2016 revises 87385as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87389 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method; HIV-1antigen(s), with HIV-1 and HIV-2 antibodies, single result

Revised -- HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies,single result

CPT® 2016 revises 87389as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87390 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method; HIV-1

Revised -- HIV-1 CPT® 2016 revises 87390as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87391 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method; HIV-2

Revised -- HIV-2 CPT® 2016 revises 87391as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87400 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Influenza, A or B, each

Revised -- Influenza, A or B, each CPT® 2016 revises 87400as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87420 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;respiratory syncytial virus

Revised -- respiratory syncytial virus CPT® 2016 revises 87420as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87425 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method; rotavirus

Revised -- rotavirus CPT® 2016 revises 87425as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87427 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method; Shiga-like toxin

Revised -- Shiga-like toxin CPT® 2016 revises 87427as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87430 Infectious agent antigendetection by enzymeimmunoassay technique,qualitative or semiquantitative,multiple-step method;Streptococcus, group A

Revised -- Streptococcus, group A CPT® 2016 revises 87430as part of a change to allcodes in the range 87301to 87430. The revisionalters the common part ofthe code descriptor for87301, which is a parentcode for 87305 to 87430,meaning that the definitionchanges for all codes inthat range. The revisionsimply adds clarifyinglanguage to give examplesof immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87449 Infectious agent antigendetection by enzymeimmunoassay techniquequalitative or semiquantitative;multiple step method, nototherwise specified, eachorganism

Revised -- Infectious agent antigendetection by immunoassaytechnique, (eg, enzymeimmunoassaytechnique[EIA], enzyme-linked immunosorbentassay [ELISA],immunochemiluminometricassay [IMCA]), qualitativeor semiquantitative;multiple -step method, nototherwise specified, eachorganism

CPT® 2016 revises 87449as part of a change to allcodes in the range 87449to 87451. The revisionalters the common part ofthe code descriptor for87449, which is a parentcode for 87450 and87451, meaning that thedefinition changes for allcodes in that range. Therevision simply addsclarifying language to giveexamples of immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87450 Infectious agent antigendetection by enzymeimmunoassay techniquequalitative or semiquantitative;single step method, nototherwise specified, eachorganism

Revised -- single step method, nototherwise specified, eachorganism

CPT® 2016 revises 87450as part of a change to allcodes in the range 87449to 87451. The revisionalters the common part ofthe code descriptor for87449, which is a parentcode for 87450 and87451, meaning that thedefinition changes for allcodes in that range. Therevision simply addsclarifying language to giveexamples of immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87451 Infectious agent antigendetection by enzymeimmunoassay techniquequalitative or semiquantitative;multiple step method,polyvalent for multipleorganisms, each polyvalentantiserum

Revised -- multiple step method,polyvalent for multipleorganisms, eachpolyvalent antiserum

CPT® 2016 revises 87451as part of a change to allcodes in the range 87449to 87451. The revisionalters the common part ofthe code descriptor for87449, which is a parentcode for 87450 and87451, meaning that thedefinition changes for allcodes in that range. Therevision simply addsclarifying language to giveexamples of immunoassaytechniques, such asenzyme immunoassay(EIA), enzyme-linkedimmunosorbent assay(ELISA), orimmunochemiluminometricassay (IMCA). You shouldnot change how you usethe codes.

87502 Infectious agent detection bynucleic acid (DNA or RNA);influenza virus, for multipletypes or sub-types, includesmultiplex reverse transcriptionand multiplex amplified probetechnique, first 2 types or sub-types

Revised -- influenza virus, for multipletypes or sub-types,includes multiplex reversetranscription, whenperformed, and multiplexamplified probe technique,first 2 types or sub-types

CPT® 2016 revises 87502to clarify that the codeincludes multiplex reversetranscription, if performed.In 2015, the codedefinition specifiedmultiplex reversetranscription as part of theprocedure, but not everytest of this type involves areverse transcription step.The code revision in 2016specifies that the multiplexreverse transcription isoptional, so you canaccurately use the codewith or without that step.

87503 Infectious agent detection bynucleic acid (DNA or RNA);influenza virus, for multipletypes or sub-types, includesmultiplex reverse transcriptionand multiplex amplified probetechnique, each additionalinfluenza virus type or sub-typebeyond 2 (List separately inaddition to code for primaryprocedure)

Revised -- influenza virus, for multipletypes or sub-types,includes multiplex reversetranscription, whenperformed, and multiplexamplified probe technique,each additional influenzavirus type or sub-typebeyond 2 (List separatelyin addition to code forprimary procedure)

CPT® 2016 revises+87503 to clarify that thecode includes multiplexreverse transcription, ifperformed. In 2015, thecode definition specifiedmultiplex reversetranscription as part of theprocedure, but not everytest of this type involves areverse transcription step.The code revision in 2016specifies that the multiplexreverse transcription isoptional, so you canaccurately use the codewith or without that step.

88346 Immunofluorescent study,each antibody; direct method

Revised -- ImmunofluorescentstudyImmunofluorescence,each antibodyperspecimen; directmethodinitial singleantibody stain procedure

CPT® 2016 revises parentcode 88346,Immunofluorescence, perspecimen; initial singleantibody stain procedure,so that the code no longerspecifies directfluorescence studies, butalso includes indirectfluorescence studies usinga single antibody stain.CPT® 2016 also deletes88347 for indirectfluorescence studies, andadds +88350 to describeeach additional antibodystain for additionalfluorescence studies onthe same specimen.

88347 Immunofluorescent study,each antibody; indirect method

Deleted (88347 hasbeen deleted.To report, see88346, 88350)

CPT® 2016 deletes88347, which describes atissue or cellularimmunofluorescent studyusing an indirect-methodsingle antibody stain. Thisdeletion is part of anoverall revision of how youshould reportimmunofluorescentstudies. CPT® currentlyprovides two codes forimmunofluorescentstudies: 88346 for directmethod and 88347 forindirect method. CPT®2016 revises 88346 torepresent a single-antibodyimmunofluorescent studyby either direct or indirectmethods, and adds new-code +88350 for eachadditional single-antibodyimmunofluorescent studyby either direct or indirectmethods. Crosswalk your88347 tests to 88346 foran initial antibodyimmunofluorescent study,or to +88350 for asubsequent antibodyimmunofluorescent studybeginning in 2016.